<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dexamethasone (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dexamethasone (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dexamethasone (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11651" href="/d/html/11651.html" rel="external">see "Dexamethasone (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15964" href="/d/html/15964.html" rel="external">see "Dexamethasone (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8015648"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Active Injection D [DSC];</li>
<li>Decadron [DSC];</li>
<li>Dexabliss;</li>
<li>dexAMETHasone Intensol;</li>
<li>DexPak 10 Day [DSC];</li>
<li>DexPak 13 Day [DSC];</li>
<li>DexPak 6 Day [DSC];</li>
<li>DoubleDex;</li>
<li>Dxevo 11-Day [DSC];</li>
<li>Hemady;</li>
<li>HiDex 6-Day;</li>
<li>MAS Care-Pak;</li>
<li>ReadySharp dexAMETHasone [DSC];</li>
<li>TaperDex 12-Day;</li>
<li>TaperDex 6-Day;</li>
<li>TaperDex 7-Day;</li>
<li>TopiDex;</li>
<li>ZCORT 7-Day [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869109"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Dexamethasone;</li>
<li>Dexamethasone Omega Unidose;</li>
<li>Dexamethasone-Omega;</li>
<li>Odan-Dexamethasone;</li>
<li>PMS-Dexamethasone;</li>
<li>PMS-Dexamethasone Sod Phosphat [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8016759"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-inflammatory Agent;</li>
<li>
                        Antiemetic;</li>
<li>
                        Corticosteroid, Systemic</li></ul></div>
<div class="block doa drugH1Div" id="F8015752"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize glucocorticoid dosing and use the minimum effective dose/duration. Evidence to support an optimal dose and duration is lacking for most indications; recommendations provided are general guidelines only.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>HPA-axis suppression is likely in any adult receiving &gt;3 mg/day (daytime dosing) or ≥0.75 mg per 24 hours (evening or night dosing) for &gt;2 weeks or with Cushingoid appearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furst.2','lexi-content-ref-27105755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furst.2','lexi-content-ref-27105755'])">Ref</a></span>); do not abruptly discontinue treatment in these patients; dose tapering may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12594318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12594318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range: </b>
<b>Oral, IV, IM:</b> 4 to 20 mg/day given in a single daily dose or in 2 to 4 divided doses; <i>High dose:</i> 0.4 to 0.8 mg/<b>kg</b>/day (usually not to exceed 40 mg/day).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd16fef4-4269-4b7a-b191-7f078cf91f01">Acute mountain sickness/high-altitude cerebral edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute mountain sickness/high-altitude cerebral edema (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Prevention, moderate- to high-risk situations</i>
<i>(alternative agent):</i></b>
<b>Note:</b> Use in addition to gradual ascent and start the day of ascent.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 2 mg every 6 hours <b>or</b> 4 mg every 12 hours; may be discontinued after staying at the same elevation for 2 to 4 days or if descent is initiated. Due to adverse effects, limit duration to ≤10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25498261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25498261'])">Ref</a></span>); some experts limit to ≤7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.1'])">Ref</a></span>). In situations of rapid ascent to altitudes &gt;3,500 meters (eg, rescue or military operations), 4 mg every 6 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25498261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25498261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Acute mountain sickness (moderate to severe)</i>:</b>
<b>Note</b>: Dexamethasone does not facilitate acclimatization; further ascent should be delayed until patient is asymptomatic off medication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.1','lexi-content-ref-25498261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.1','lexi-content-ref-25498261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral, IM, IV:</b> 4 mg every 6 hours, continue until 24 hours after symptoms resolve or descent completed (not longer than 7 days total) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.1','lexi-content-ref-25498261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.1','lexi-content-ref-25498261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>High-altitude cerebral edema:</i></b>
<b>Oral, IM, IV:</b> 8 mg as a single dose, followed by 4 mg every 6 hours until descent is complete and symptoms resolve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25498261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25498261'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54822daa-4bb4-4bf6-8619-0111182f0825">Acute respiratory distress syndrome, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute respiratory distress syndrome, moderate to severe (off-label use): Note:</b> May consider in most patients with persistent or refractory moderate to severe acute respiratory distress syndrome who are relatively early in the disease course (within 14 days). Do not abruptly discontinue since this may cause deterioration due to inflammatory response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28938253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28938253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 20 mg once daily from days 1 to 5, then 10 mg once daily from days 6 to 10 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32043986']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32043986'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1d6777-46ae-46c3-8e98-9fa4937de2f2">Adrenal insufficiency, adrenal crisis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, adrenal crisis (alternative agent):</b>
<b>Note:</b> Dexamethasone should only be used if hydrocortisone is unavailable. Corticosteroid therapy should be combined with adequate fluid resuscitation in patients with primary adrenal insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4 mg every 12 hours; transition to hydrocortisone as soon as possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044','lexi-content-ref-Nieman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044','lexi-content-ref-Nieman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc00fdd1-dcbe-4bc8-aeed-8fa0399f4f39">Adrenal insufficiency, primary chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, primary chronic (alternative agent): Note:</b> For use in patients who are unable to tolerate treatment with other glucocorticoids (hydrocortisone is preferred); risk of overreplacement may be higher with dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044','lexi-content-ref-Nieman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044','lexi-content-ref-Nieman.1'])">Ref</a></span>). Use in conjunction with fludrocortisone. Dose is based on prednisolone equivalency.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic maintenance dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Usual dosage range: 0.25 to 0.75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nieman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nieman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Stress dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients who are unable to tolerate oral medication (eg, due to vomiting or diarrhea), are in active labor, or are under surgical stress may require parenteral corticosteroid therapy (preferably with hydrocortisone) to prevent adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with febrile illness: </i>
<b>Oral: </b>Double the chronic maintenance dose until recovery for fever 38°C (100.4°F) to 39°C (102.2°F) or triple the chronic maintenance dose until recovery for fever &gt;39°C (102.2°F), then return to baseline dose within 1 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Minor surgical stress (eg, hernia repair, procedures with local anesthetic</i>
<i>): </i>
<b>Oral:</b> Continue chronic maintenance dose (no additional supplementation needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11779267','lexi-content-ref-Hamrahian.1','lexi-content-ref-8161268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11779267','lexi-content-ref-Hamrahian.1','lexi-content-ref-8161268'])">Ref</a></span>); may give an additional 0.75 mg (equivalent to ~20 mg hydrocortisone) postoperatively if signs or symptoms of adrenal insufficiency are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-24330030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-24330030'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="06e752d6-05c8-4c90-813c-f4dc2ffeb0ca">Antiemetic regimens: Chemotherapy-associated nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiemetic regimens: Chemotherapy-associated nausea and vomiting, prevention (off-label use): Note: </b>When dexamethasone is given with rolapitant in a prechemotherapy regimen, the oral route for both is generally used. When checkpoint inhibitor therapy is administered in combination with emetogenic chemotherapy, there is no evidence to omit dexamethasone from the prophylactic antiemetic regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Single-day IV chemotherapy regimens: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Highly emetogenic chemotherapy </b>
<b>(&gt;90% risk of emesis):</b>
<b>Cisplatin and other highly emetogenic single agents:</b>
<i></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dexamethasone dose depends on specific neurokinin 1 (NK<sub>1</sub>) receptor antagonist: </i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Day of chemotherapy: </b></i>Administer prior to chemotherapy <b>and</b> in combination with an NK<sub>1 </sub>receptor antagonist, and a 5-HT<sub>3</sub> receptor antagonist, with or without olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">In combination with aprepitant, fosaprepitant, netupitant/palonosetron (NEPA), or fosnetupitant/palonosetron:<b> Oral, IV:</b> 12 mg.</p>
<p style="text-indent:-2em;margin-left:12em;">In combination with rolapitant: <b>Oral, IV:</b> 20 mg.</p>
<p style="text-indent:-2em;margin-left:12em;">If NK<sub>1</sub> receptor antagonist not used: <b>Oral, IV:</b> 20 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Postchemotherapy days:</b></i></p>
<p style="text-indent:-2em;margin-left:12em;">If aprepitant given: <b>Oral, IV:</b> 8 mg once daily on days 2 to 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">If fosaprepitant given: <b>Oral, IV:</b> 8 mg once on day 2, followed by 8 mg twice daily on days 3 and 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">If NEPA or fosnetupitant/palonosetron given: Prophylaxis with dexamethasone on subsequent days is not needed unless regimen contained cisplatin:<b> Oral, IV:</b> 8 mg once daily on days 2 to 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hesketh.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hesketh.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">If rolapitant given: <b>Oral, IV:</b> 8 mg twice daily on days 2 to 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">If NK<sub>1</sub> receptor antagonist not used: <b>Oral, IV:</b> 8 mg twice daily on days 2 to 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Highly emetogenic chemotherapy </b>
<b>(&gt;90% risk of emesis):</b>
<b>Breast cancer</b>
<b>regimens that include an anthracycline combined with cyclophosphamide:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dexamethasone dose depends on specific NK<sub>1</sub> receptor antagonist: </i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Day of chemotherapy:</b></i> Administer prior to chemotherapy <b>and</b> in combination with an NK<sub>1</sub> receptor antagonist, and a 5-HT<sub>3</sub> receptor antagonist, with or without olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">In combination with aprepitant, fosaprepitant, NEPA, fosnetupitant/palonosetron: <b>Oral, IV:</b> 12 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">In combination with rolapitant: <b>Oral, IV:</b> 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">If NK<sub>1</sub> receptor antagonist not used: <b>Oral, IV:</b> 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Postchemotherapy days: </i></b>Dexamethasone use is not recommended (an alternative agent or agents is/are recommended) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderately emetogenic chemotherapy (30% to 90% risk of emesis): Carboplatin-based regimens:</b>
<i></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dexamethasone dose depends on specific NK<sub>1</sub> receptor antagonist</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Day of chemotherapy: </b></i>Administer prior to chemotherapy <b>and</b> in combination with an NK<sub>1</sub> receptor antagonist and a 5-HT<sub>3</sub> receptor antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">In combination with aprepitant, fosaprepitant, NEPA, or fosnetupitant/palonosetron:<b> Oral, IV:</b> 12 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">In combination with rolapitant: <b>Oral, IV:</b> 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>
<i>Postchemotherapy days: </i></b></i>Prophylaxis is not necessary on subsequent days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderately emetogenic chemotherapy (30% to 90% risk of emesis): Non-carboplatin-based regimens: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Day of chemotherapy:</i></b> Administer prior to chemotherapy <b>and</b> in combination with a 5-HT<sub>3</sub> receptor antagonist: <b>Oral, IV:</b> 8 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Postchemotherapy days:</i></b>
<b>Note:</b> Consider single-agent dexamethasone use for regimens containing agents with known potential to induce delayed emesis (eg, oxaliplatin, cyclophosphamide, doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); a single-day dexamethasone regimen may be employed when utilizing palonosetron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25872578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25872578'])">Ref</a></span>); however, if a first-generation 5-HT<sub>3</sub> antagonist was used on day 1 rather than palonosetron, some experts suggest the first-generation 5-HT<sub>3</sub> receptor antagonist be continued for postchemotherapy emetic prophylaxis on days 2 and 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hesketh.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hesketh.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral, IV:</b> 8 mg on days 2 and 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Low emetogenic risk (10% to 30% risk of emesis): Oral, IV:</b> 4 to 8 mg administered as a single agent in a single dose prior to chemotherapy; prophylaxis is not necessary on subsequent days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-Hesketh.2019','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-Hesketh.2019','lexi-content-ref-27664248'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1755677-3f46-4a23-a4df-4301b1814513">Antiemetic regimens: Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiemetic regimens: </b>
<b>Postoperative nausea and vomiting, prevention (off-label use): Note:</b> May be used alone or in combination with one or more other prophylactic interventions depending on risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223115','lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223115','lexi-content-ref-32467512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4 to 10 mg once, before or after induction of anesthesia. Dose depends on risk and type of surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-Joshi.1','lexi-content-ref-11093989','lexi-content-ref-10866900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-Joshi.1','lexi-content-ref-11093989','lexi-content-ref-10866900'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11349e99-2146-4045-8e44-ece462273b6d">Antiemetic regimens: Radiation therapy-associated nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiemetic regimens: </b>
<b>Radiation therapy-associated nausea and vomiting, prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>High emetogenic risk radiation therapy (total body irradiation): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Radiation day(s):</i> Oral, IV:</b> 4 mg once daily prior to each fraction of radiation; give in combination with a 5-HT<sub>3</sub> receptor antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Postradiation days:</i></b>
<b>Oral, IV:</b> The appropriate duration of therapy following radiotherapy days is not well defined; ASCO guidelines recommend continuing dexamethasone 4 mg once on the day after each day of radiation if radiation is not planned for that day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Moderate emetogenic risk radiation therapy (upper abdomen, craniospinal irradiation):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Radiation day(s):</i></b>
<b>Oral, IV:</b> 4 mg once daily prior to each of the first 5 fractions of radiation; give in combination with a 5-HT<sub>3</sub> receptor antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85b2fb27-1a4a-40d6-b8b5-ab95601995d8">Asthma, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation (alternative agent) (off-label use):</b>
<b>Note:</b> Alternative to a longer course of other corticosteroids in mild to moderate exacerbations or in patients who do not respond promptly and completely to short-acting beta-agonists; administer within 1 hour of presentation to emergency department (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 12 to 16 mg daily for 1 to 2 days only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21334098','lexi-content-ref-27117874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21334098','lexi-content-ref-27117874'])">Ref</a></span>); longer treatment at this dose may be associated with metabolic adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8edf0a5-60ec-4726-9477-5ef05e725995">Cancer-related cachexia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cancer-related cachexia (off-label use): Oral: </b>3 to 4 mg once daily; short-term therapy (weeks) is recommended, although duration of treatment depends on treatment goals and risk/benefit assessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32432946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32432946'])">Ref</a></span>) <b>or</b> 3 to 6 mg/day for up to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23953794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23953794'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e144c50-4c2a-4cd4-996d-e2a0e7a531d7">Cancer-related pain, advanced cancer, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cancer-related pain, advanced cancer, adjuvant therapy (off-label use): Note: </b>Although available data are limited and with mixed results, dexamethasone may provide clinical benefit in the management of a variety of types of pain in patients with advanced cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>). Due to the risk for potential toxicity, carefully consider the risks and benefits of glucocorticoid use for treating cancer-related pain, including the availability of other treatments, duration of treatment, other symptoms, and life expectancy.</p>
<p style="text-indent:-2em;margin-left:4em;">Low-dose regimen for pain and other symptoms in the context of advanced cancer and short prognosis<i>:</i>
<b>Oral, IV: Initial: </b>0.75 to 1.5 mg once or twice daily; usual effective dose range: 1 to 2 mg IV or orally twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Higher-dose regimen for pain crisis that is poorly responsive to initial opioid therapy:</i>
<b>Oral, IV:</b> Initial: 8 to 10 mg once; if responsive, then may consider 4 mg twice daily or 8 mg once daily; use the lowest dose that maintains pain relief while other analgesic treatments are added, if indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0bb5701-33b8-49a3-90a4-9b238a89fddb">Cerebral edema associated with brain tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebral (vasogenic) edema associated with brain tumor: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Moderate to severe symptoms (eg, lowered consciousness/brainstem dysfunction)</i>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>IV:</b> 10 mg once followed by maintenance dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8164824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8164824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: <b>IV, Oral:</b> 4 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30883663','lexi-content-ref-8164824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30883663','lexi-content-ref-8164824'])">Ref</a></span>). <b>Note: </b>Consider taper after 7 days of therapy; taper slowly over several weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19957014','lexi-content-ref-8164824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19957014','lexi-content-ref-8164824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Mild symptoms:</i></b>
<b>IV, Oral:</b> 4 to 8 mg/day in 1 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30883663','lexi-content-ref-8164824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30883663','lexi-content-ref-8164824'])">Ref</a></span>). <b>Note:</b> Consider taper after 7 days of therapy; taper slowly over several weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19957014','lexi-content-ref-8164824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19957014','lexi-content-ref-8164824'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="894e2a7e-3fff-4cb6-8ddb-f11aa30fb548">COVID-19, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dexamethasone is recommended for treatment of COVID-19 in hospitalized patients requiring supplemental oxygen or ventilatory support (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2'])">Ref</a></span>). An equivalent dose of an alternative glucocorticoid may be substituted if dexamethasone is unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Horby.2020','lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Horby.2020','lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 6 mg once daily for up to 10 days (or until discharge if sooner) as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Horby.2020','lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Horby.2020','lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee79cdca-75a6-48fb-8941-7238135e3db1">Cushing syndrome, diagnosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cushing syndrome, diagnosis: Note: </b>Interpretation requires evaluation of one or more of the following: serum cortisol concentration, serum dexamethasone concentration, urinary cortisol excretion, or 17-hydroxycorticosteroid excretion; consultation with a clinical endocrinologist is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18334580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18334580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial testing:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Overnight 1 mg dexamethasone suppression test:</i>
<b> Oral:</b> 1 mg given once between 11 PM and 12 AM (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18334580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18334580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Longer low-dose <i>dexamethasone suppression test</i> (2 mg/day for 48 hours):</i>
<b> Note: </b>May be preferred in patients with depression, anxiety, obsessive-compulsive disorder, morbid obesity, alcoholism, or diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18334580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18334580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 0.5 mg every 6 hours for 48 hours for a total of 8 doses; start time varies (eg, 9 AM <b>or </b> 12 PM) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18334580','lexi-content-ref-8386285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18334580','lexi-content-ref-8386285'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ad4d9ab-fdd1-48c6-9233-a7bd4548c7a1">Fetal lung maturation, acceleration of</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fetal lung maturation, acceleration of (maternal administration) (off-label use):</b>
<b>Note:</b> Generally, for patients between 24 and 34 weeks of gestation, including those with ruptured membranes or multiple gestations, who are at risk of delivering within 7 days. A single course may be appropriate in some pregnant patients beginning at 22 weeks' gestation or late preterm (between 34 0/7 weeks' and 36 6/7 weeks' gestation) who are at risk of delivering within 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 6 mg every 12 hours for a total of 4 doses. May repeat course in select patients (eg, patients with pregnancies up to 34 weeks' gestation at risk for delivery within 7 days and &gt;14 days have elapsed since initial course of antenatal corticosteroids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26695585','lexi-content-ref-32080050','lexi-content-ref-28742678','lexi-content-ref-ACOG.2','lexi-content-ref-36156145','lexi-content-ref-30646235','lexi-content-ref-19853510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26695585','lexi-content-ref-32080050','lexi-content-ref-28742678','lexi-content-ref-ACOG.2','lexi-content-ref-36156145','lexi-content-ref-30646235','lexi-content-ref-19853510'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (initial therapy)<i>: </i>Note: </b>Goal of therapy is to provide a safe platelet count to prevent clinically important bleeding rather than normalization of the platelet count (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 40 mg once daily for 4 days and then stop (no taper); may be repeated up to 3 times if inadequate response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794604','lexi-content-ref-17077333','lexi-content-ref-31770441','lexi-content-ref-26480931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794604','lexi-content-ref-17077333','lexi-content-ref-31770441','lexi-content-ref-26480931'])">Ref</a></span>). For severe bleeding with thrombocytopenia, give in combination with other therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56b6caea-ebbf-4c1e-93f2-543c99fc4e9b">Iodinated contrast media allergic-like reaction, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iodinated contrast media allergic-like reaction, prevention (alternative agent): Note: </b>Generally for patients with a prior allergic-like or unknown-type iodinated contrast reaction who will be receiving another iodinated contrast agent. Nonurgent premedication with an oral corticosteroid (eg, prednisone) is generally preferred when contrast administration is scheduled to begin in ≥12 hours; however, consider an urgent (accelerated) regimen with an IV corticosteroid for those requiring contrast in &lt;12 hours. Efficacy of premedication regimens starting &lt;4 to 5 hours before the use of contrast has not been demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urgent (accelerated) regimen:</i>
<b>IV:</b> 7.5 mg every 4 hours until contrast medium administration in combination with diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="555c5a40-6cae-48d5-af2f-42aca7678272">Meningitis, prevention of neurologic complications</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis (bacterial), prevention of neurologic complications (off-label use): Note:</b> Administer first dose of dexamethasone shortly before or at the same time as the first dose of antibacterials. If antibacterials have already been administered, do <b>not</b> administer dexamethasone. In patients with pneumococcal meningitis who receive dexamethasone, some experts recommend adding rifampin to the standard initial antibacterial regimen or adding rifampin if susceptibility tests, once available, show intermediate susceptibility (MIC ≥2 mcg/mL) to ceftriaxone and cefotaxime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-Sexton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-Sexton.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Developed world (suspected or confirmed pneumococcal meningitis)</i>:<b> IV:</b> 0.15 mg/kg/dose <b>or</b> 10 mg every 6 hours for 4 days; discontinue if culture data reveal non-pneumococcal etiology (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12432041','lexi-content-ref-15494903','lexi-content-ref-29090327','lexi-content-ref-Sexton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12432041','lexi-content-ref-15494903','lexi-content-ref-29090327','lexi-content-ref-Sexton.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Developing world (strongly suspected or confirmed bacterial meningitis)</i>:<b> IV:</b> 0.4 mg/kg/dose every 12 hours for 4 days; discontinue if culture data reveal non-pneumococcal etiology; not recommended in regions with high rates of HIV infection and/or malnutrition or in cases of delayed clinical presentation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18077808','lexi-content-ref-Sexton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18077808','lexi-content-ref-Sexton.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f12f591-3737-4c2d-85d6-a7c9c4a24d75">Migraine, recurrence prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, recurrence prevention (off-label use): IM, IV:</b> 4 to 24 mg once in combination with standard migraine abortive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27300483','lexi-content-ref-37604662','lexi-content-ref-23577697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27300483','lexi-content-ref-37604662','lexi-content-ref-23577697'])">Ref</a></span>). Some experts recommend a 4 mg dose due to evidence that higher doses are not more effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18541610','lexi-content-ref-37604662','lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18541610','lexi-content-ref-37604662','lexi-content-ref-Schwedt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma</b>
<b>: Note: </b>Multiple dexamethasone-containing regimens are available. Refer to literature/guidelines for additional details. For many regimens, dexamethasone is continued until disease progression or unacceptable toxicity. Dexamethasone total weekly dose may be split over 2 days when combination therapies are administered on successive days (refer to protocol) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32682484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32682484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Frail patients </i>
<i>(eg, &gt;75 years of age, BMI &lt;18.5 kg/m<sup>2</sup>, poorly controlled diabetes, corticosteroid intolerance)</i>
<i>:</i> When administered weekly, dexamethasone is usually reduced to 20 mg once weekly for frail patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27705267','lexi-content-ref-34087126','lexi-content-ref-33763699','lexi-content-ref-27557302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27705267','lexi-content-ref-34087126','lexi-content-ref-33763699','lexi-content-ref-27557302'])">Ref</a></span>). May consider lower initial dexamethasone doses (8 to 20 mg once weekly) in patients &gt;75 years of age or those with comorbidities, with subsequent titration based on response/tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30932732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30932732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination regimens that do <b>not</b> include a monoclonal antibody:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">40 mg once weekly on days 1, 8, 15, and 22 every 28 days in combination with lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19853510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19853510'])">Ref</a></span>), pomalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24007748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24007748'])">Ref</a></span>), ixazomib and lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27119237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27119237'])">Ref</a></span>), ixazomib and lenalidomide for 18 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33763699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33763699'])">Ref</a></span>), carfilzomib and lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25482145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25482145'])">Ref</a></span>), or bortezomib and lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21181954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21181954'])">Ref</a></span>) <b>or</b> 40 mg once weekly on days 1, 8, 15, and 22 every 28 days in cycles 1 to 9, and then 40 mg once weekly on days 1, 8, and 15 every 28 days beginning at cycle 10 (in combination with carfilzomib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29866475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29866475'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:8em;">20 mg on days 1, 8, 15, and 22 every 28 days (in combination with lenalidomide) for 9 cycles, followed by lenalidomide maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33739404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33739404'])">Ref</a></span>) <b>or</b> 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12 every 21 days (in combination with bortezomib and lenalidomide) for 8 cycles (induction), followed by 40 mg on days 1, 8, 15, and 22 every 28 days (in combination with lenalidomide) for maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28017406','lexi-content-ref-32393732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28017406','lexi-content-ref-32393732'])">Ref</a></span>) <b>or</b> 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 every 28 days (in combination with carfilzomib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26671818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26671818'])">Ref</a></span>) <b>or</b> 20 mg on days 1 and 3 of each week (in combination with selinexor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31433920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31433920'])">Ref</a></span>) <b>or</b> 20 mg on days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 every 35 days (in combination with selinexor and bortezomib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33189178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33189178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:8em;">40 mg once daily on days 1 to 4 and 9 to 12 every 28 days in combination with bortezomib and lenalidomide for 6 cycles followed by transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31484647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31484647'])">Ref</a></span>) <b>or</b> 40 mg once daily on days 1 to 4, 9 to 12, and 17 to 20 every 28 days in combination with bortezomib and doxorubicin for 3 cycles as induction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22802322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22802322'])">Ref</a></span>). <b>Note:</b> Some experts reserve this dosing (for 1 cycle, followed by 40 mg once weekly thereafter) for patients with an aggressive disease presentation or acute renal failure from light chain cast nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Laubach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Laubach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination regimens that include a monoclonal antibody:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">40 mg weekly in combination with daratumumab and pomalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28637662','lexi-content-ref-34087126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28637662','lexi-content-ref-34087126'])">Ref</a></span>) or daratumumab/hyaluronidase and pomalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34087126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34087126'])">Ref</a></span>) or daratumumab and lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27705267','lexi-content-ref-31141632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27705267','lexi-content-ref-31141632'])">Ref</a></span>) or daratumumab/hyaluronidase and lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33216361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33216361'])">Ref</a></span>) <b>or</b> daratumumab and carfilzomib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32682484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32682484'])">Ref</a></span>) <b>or </b>isatuximab and pomalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31735560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31735560'])">Ref</a></span>) or 20 mg once daily on days 1, 2, 4, 5, 8, 9, 11, and 12 every 21 days in combination with daratumumab and bortezomib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27557302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27557302'])">Ref</a></span>) <b>or</b> 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 every 28 days in combination with isatuximab and carfilzomib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34097854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34097854'])">Ref</a></span>). <b>Note:</b> In some studies, the dexamethasone dose is split over 2 days (20 mg before daratumumab and 20 mg the day after daratumumab infusion).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:8em;">40 mg weekly, except on days elotuzumab is administered (administer dexamethasone 28 mg orally [8 mg orally in patients &gt;75 years of age] plus 8 mg IV prior to elotuzumab) in combination with elotuzumab and pomalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30403938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30403938'])">Ref</a></span>) or elotuzumab and lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26035255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26035255'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="718897c9-e5f2-49a3-ac81-47d294b04c4c">Neoplastic epidural spinal cord compression, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neoplastic epidural spinal cord compression, symptomatic: Note:</b> As an adjunct to definitive treatment (radiotherapy or surgery), particularly in patients with neurologic deficits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22420969','lexi-content-ref-22171401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22420969','lexi-content-ref-22171401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b> (initial dose): 10 or 16 mg followed by oral dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22420969','lexi-content-ref-22171401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22420969','lexi-content-ref-22171401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (after IV dose): 16 mg/day (usually given in 2 to 4 divided doses). Once definitive treatment is underway, taper gradually over 1 to 2 weeks until discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26337716','lexi-content-ref-28437329','lexi-content-ref-22420969','lexi-content-ref-22171401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26337716','lexi-content-ref-28437329','lexi-content-ref-22420969','lexi-content-ref-22171401'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1e894c0-b02f-4f9c-8405-66ea001446f3">Tuberculosis, central nervous system</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, central nervous system: Note:</b> In general, steroids are indicated for patients with established or suspected tuberculous meningitis, regardless of HIV status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-WHO.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial dose: 0.3 to 0.4 mg/kg/day for 2 weeks, then 0.2 mg/kg/day for week 3, then 0.1 mg/kg/day for week 4, followed by <b>oral</b> therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leonard.1','lexi-content-ref-15496623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leonard.1','lexi-content-ref-15496623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Starting week 5 of treatment: 4 mg/day, then taper by 1 mg of the daily dose each week; total combined IV/oral therapy duration: ~8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leonard.1','lexi-content-ref-15496623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leonard.1','lexi-content-ref-15496623'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991446"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The pharmacokinetics and pharmacodynamics of corticosteroids in kidney impairment are not well understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032','lexi-content-ref-25471548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032','lexi-content-ref-25471548'])">Ref</a></span>). Dexamethasone half-life is decreased in patients with severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3980669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3980669'])">Ref</a></span>), potentially due to decreased protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032'])">Ref</a></span>); however, the clinical implications of these findings are unclear.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, parenteral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988753"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F57134096"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2 and 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV, IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Non–weight-based dosing: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: Use<b> ideal body weight</b> to avoid overdosing and subsequent toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b> Corticosteroids are lipophilic compounds; however, the reported pharmacokinetic variability due to obesity is limited and inconsistent. Two small studies evaluated pharmacokinetic changes with oral dexamethasone in patients with obesity. One study reported lower AUC in patients with obesity compared to patients with normal weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35706350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35706350'])">Ref</a></span>), while another study reported a positive correlation between actual body weight and AUC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2399513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2399513'])">Ref</a></span>). Weight-based dosing using actual body weight could lead to supratherapeutic levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30928086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30928086'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F8015753"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use cautiously in the elderly at the lowest possible dose.</p></div>
<div class="block dop drugH1Div" id="F8015751"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15964" href="/d/html/15964.html" rel="external">see "Dexamethasone (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9116062-427d-4715-8eda-5d582e2630c5">COVID-19, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, treatment:</b> Very limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Safety and effectiveness of dexamethasone or other corticosteroids for COVID-19 treatment have not been sufficiently evaluated in pediatric patients; use is extrapolated from adult patients; use caution. Reserve use for hospitalized patients who require high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); not routinely recommended for pediatric patients requiring low levels of oxygen support (ie, nasal canula only). Use in profoundly immunocompromised pediatric patients should be considered only on a case-by-case basis as it has not been evaluated and may be harmful. Pediatric patients with COVID-19 should be enrolled in clinical trials whenever possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, Oral: 0.15 to 0.3 mg/kg/dose once daily for up to 10 days; maximum dose: 6 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-NIH.2021','lexi-content-ref-33833623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-NIH.2021','lexi-content-ref-33833623'])">Ref</a></span>). <b>Note:</b> An equivalent dose of an alternative glucocorticoid may be substituted if dexamethasone is unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-NIH.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-NIH.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81bd00e2-ca6c-4403-8d1d-ae1ea898f968">Acute mountain sickness/high-altitude cerebral edema, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute mountain sickness (AMS) (moderate)/high-altitude cerebral edema (HACE), treatment: </b>Limited data available: <b>Note: </b>Dexamethasone does not facilitate acclimatization; further ascent should be delayed until patient is asymptomatic off medication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral, IM, IV: 0.15 mg/kg/dose every 6 hours; maximum dose: 4 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248818','lexi-content-ref-11682018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248818','lexi-content-ref-11682018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="441e2279-5fc2-4752-820e-480563ec07b7">Airway edema or extubation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Airway edema or extubation:</b> Limited data available: Infants, Children, and Adolescents: Oral, IM, IV: 0.5 mg/kg/dose (maximum dose: 10 mg/dose) administered 6 to 12 hours prior to extubation then every 6 hours for 6 doses (total dexamethasone dose: 3 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-8874303','lexi-content-ref-19588321','lexi-content-ref-1993963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-8874303','lexi-content-ref-19588321','lexi-content-ref-1993963'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="462a3a59-e36e-4308-9661-36c83a515c19">Anti-inflammatory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory:</b> Infants, Children, and Adolescents: Oral, IM, IV: Initial dose range: 0.02 to 0.3 mg/kg/<b>day</b>
<b>or</b> 0.6 to 9 mg/<b>m<sup>2</sup>/day</b> in divided doses every 6 to 12 hours; dose depends upon condition being treated and response of patient; dosage for infants and children should be based on disease severity and patient response; usual adult initial daily dose range: 0.75 to 9 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a6a225f-30c9-4795-b950-be16101787e4">Asthma exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma exacerbation:</b> Limited data available: Infants, Children, and Adolescents: Oral, IM, IV: 0.6 mg/kg once daily as a single dose or once daily for 2 days; maximum dose: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-GINA.2020','lexi-content-ref-24515516','lexi-content-ref-11445789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-GINA.2020','lexi-content-ref-24515516','lexi-content-ref-11445789'])">Ref</a></span>); single dose regimens as low as 0.3 mg/kg/dose and as high as 1.7 mg/kg/dose have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24515516','lexi-content-ref-11445789','lexi-content-ref-19602654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24515516','lexi-content-ref-11445789','lexi-content-ref-19602654'])">Ref</a></span>). <b>Note: </b> Duration &gt;2 days is not recommended due to increased risk of metabolic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7496b4ee-5cac-4c49-ada3-acfb4a3fc2b8">Bacterial meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial meningitis (<i>Haemophilus influenzae</i> type b):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;6 weeks and Children: IV: 0.15 mg/kg/dose every 6 hours for the first 2 to 4 days of antibiotic treatment; start dexamethasone 10 to 20 minutes before or with the first dose of antibiotic; if antibiotics have already been administered, dexamethasone use has not been shown to improve patient outcome and is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>). <b>Note:</b> For pneumococcal meningitis, efficacy results are variable and use is controversial; risk and benefits should be considered prior to use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a591fe7f-9113-42e0-b719-a9780d9c1d5a">Cerebral edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebral edema:</b> Limited data available: <b>Note:</b> Dose, route, and duration may vary due to underlying cause of edema; tapering may be required. Infants, Children, and Adolescents: Oral, IM, IV: Loading dose: 1 to 2 mg/kg/dose as a single dose; maintenance: 1 to 2 mg/kg/<b>day</b> in divided doses every 4 to 6 hours; maximum daily dose: 16 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007','lexi-content-ref-371348','lexi-content-ref-3304622','lexi-content-ref-6621810','lexi-content-ref-32026434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007','lexi-content-ref-371348','lexi-content-ref-3304622','lexi-content-ref-6621810','lexi-content-ref-32026434'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="170299cf-a590-4ce2-b509-66903788defc">Chemotherapy-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention</b>: Reported regimens variable; optimal dose not established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32970373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32970373'])">Ref</a></span>). Refer to individual protocols and emetogenic potential:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">POGO recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23512831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23512831'])">Ref</a></span>): <b>Note:</b> Reduce dose by 50% if administered concomitantly with aprepitant:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Highly/severely emetogenic chemotherapy:</i> Oral, IV: 6 mg/<b>m<sup>2</sup></b>/dose every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Moderately emetogenic chemotherapy:</i> Oral, IV:</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≤0.6 m<sup>2</sup>: 2 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">BSA &gt;0.6 m<sup>2</sup>: 4 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Alternate dosing: <i>Highly/severely emetogenic chemotherapy:</i> IV: Usual: 10 mg/<b>m<sup>2</sup></b>/dose once daily on days of chemotherapy; some patients may require every 12-hour dosing; usual range: 8 to 14 mg/<b>m<sup>2</sup></b>/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16404740','lexi-content-ref-20824481','lexi-content-ref-20824866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16404740','lexi-content-ref-20824481','lexi-content-ref-20824866'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e58012da-026c-41dd-80fe-2f3b7e31cf6d">Congenital adrenal hyperplasia, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia, maintenance:</b> Adolescents (fully grown): Oral: 0.25 to 0.5 mg once daily; use of a liquid dosage form may be preferable to allow for better dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>). <b>Note:</b> For younger patients who are still growing, hydrocortisone or fludrocortisone are preferred.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6c128f7-ce59-4f5f-9af0-87e9cf54b487">Croup</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Croup (laryngotracheobronchitis):</b> Limited data available; dosing regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral, IM, IV: 0.6 mg/kg once; reported maximum dose highly variable; usual maximum dose: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-31871244'])">Ref</a></span>); in trials, maximum doses of 10 to 20 mg/dose have been reported with similar efficacy findings for mild to moderate croup. The majority of reported experience in infants are those ≥3 months of age; data available in &lt;3 months of age is very limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15385657','lexi-content-ref-7630673','lexi-content-ref-24596395','lexi-content-ref-21249651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15385657','lexi-content-ref-7630673','lexi-content-ref-24596395','lexi-content-ref-21249651'])">Ref</a></span>). In one evaluation of 22 children &gt;2 years of age, a maximum dose of 12 mg/dose (at 0.6 mg/kg/dose) did not decrease endogenous glucocorticoid levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28398936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28398936'])">Ref</a></span>). A single oral dose of 0.15 mg/kg has also been shown effective in infants ≥3 months and children with mild to moderate croup (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14973975','lexi-content-ref-16624882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14973975','lexi-content-ref-16624882'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51093752"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: IM, IV, Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Kidney impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis or peritoneal dialysis: Based on adult data, supplemental dose is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51093753"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55850064"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Adrenal suppression (tertiary adrenal insufficiency)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal suppression</b> (tertiary adrenal insufficiency) may occur with glucocorticoids, including dexamethasone, and results from inadequate stimulation of the adrenal glands (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akahoshi.1','lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akahoshi.1','lexi-content-ref-31223468'])">Ref</a></span>). Glucocorticoid-induced adrenal insufficiency usually resolves with discontinuation of dexamethasone, but symptoms may persist for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34253540','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34253540','lexi-content-ref-29184808'])">Ref</a></span>). Adrenal insufficiency may lead to adrenal crisis, a life-threatening emergency that may present like a hypotensive shock state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; occurs due to lack of or diminished cortisol production by the adrenal gland (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468','lexi-content-ref-29184808'])">Ref</a></span>). Exogenous glucocorticoids produce a similar negative feedback mechanism as endogenous cortisol, causing a subsequent decrease in adrenocorticotrophic hormone (ACTH) secretion; thus, cortisol production is suppressed resulting in adrenal atrophy and subsequent insufficiency (ie, hypothalamic-pituitary-adrenal-axis [HPA-axis] suppression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468','lexi-content-ref-29184808'])">Ref</a></span>). In times of stress (eg, critical illness, trauma, surgery), the body requires stress doses in patients taking dexamethasone chronically (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>). Primary adrenal insufficiency can be caused by dexamethasone alone (without fludrocortisone) because of its lack of mineralocorticoid activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; acute (minutes after administration) and/or chronic (2 to 20 hours to days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184808'])">Ref</a></span>). Chronic dexamethasone use does not allow for the HPA axis to recover quickly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses for prolonged periods: Although some patients may become HPA suppressed with lower doses or briefer exposure, some experts consider HPA axis-suppression likely in any adult receiving a dose comparable to prednisone &gt;20 mg/day (daytime dosing) or a dose comparable to prednisone ≥5 mg per 24 hours (evening or night dosing) for &gt;3 weeks or with cushingoid appearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27105755','lexi-content-ref-33923971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27105755','lexi-content-ref-33923971'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Potency of glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>); dexamethasone is the most potent glucocorticoid for suppressing the HPA axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29858690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29858690'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent interacting medications (eg, carbamazepine, St John's wort, mitotane, rifampicin, itraconazole, diltiazem, thyroid replacement therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of previous adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of glucocorticoid therapy delivered by various routes of administration (oral and inhaled greater risk than topical or intra-articular) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akahoshi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akahoshi.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS and psychiatric/behavioral effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including dexamethasone, may cause a myriad of CNS and psychiatric/behavioral adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696'])">Ref</a></span>). Patients may develop <b>apathy</b> or <b>depression</b>. More commonly, patients develop excitatory <b>psychiatric disturbances</b> (including agitation, anxiety, distractibility, fear, hypomania, insomnia, irritability, lethargy, labile mood, mania, pressured speech, restlessness, and tearfulness) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-17036562'])">Ref</a></span>). Exact incidences are unclear but range from 1.8% to 57% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17036562'])">Ref</a></span>). Severe psychiatric effects have been reported in 6% of adults receiving high-dose regimens, while depression or mania have been reported in 36% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24943696'])">Ref</a></span>). Discontinuation or dose reductions generally resolve symptoms over days to weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24943696','lexi-content-ref-26034636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24943696','lexi-content-ref-26034636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; not clearly established. Dexamethasone and other glucocorticoids may alter feedback on the hypothalamic-pituitary-adrenal axis, which may lead to mood changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31656440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31656440'])">Ref</a></span>). Glucocorticoids may induce glutamate release, which may be responsible for neuronal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992'])">Ref</a></span>). Exogenous glucocorticoids may also impact GABAergic steroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23157995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23157995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases occur early in treatment (within the first 5 days), average of 11.5 days. The majority develop within 6 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-26034636','lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-26034636','lexi-content-ref-17036562'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (comparable to ≥80 mg prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-17036562'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Possible additional risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;30 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22764363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22764363'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17036562'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of neuropsychiatric disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22764363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22764363'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cushingoid features/Cushing syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glucocorticoids may cause a cushingoid appearance</b> (truncal obesity, facial adipose tissue, dorsocervical adipose tissue), which are adverse reactions related to patient's physical features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848','lexi-content-ref-23947590'])">Ref</a></span>). Reactions are more metabolic than <b>weight gain</b>, which is related to <b>fluid retention</b> (<b>edema</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848','lexi-content-ref-23947590'])">Ref</a></span>). Iatrogenic <b>Cushing syndrome </b>resulting from glucocorticoid therapy increases morbidity and mortality and decreases quality of life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27177728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27177728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; excess cortisol from exogenous source (dexamethasone) results in suppression of adrenocorticotrophic hormone (ACTH), commonly called iatrogenic <b>Cushing syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848','lexi-content-ref-24910822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848','lexi-content-ref-24910822'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; may develop within the first 2 months of dexamethasone therapy, with the risk dependent on the dose and duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18684744','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18684744','lexi-content-ref-23947590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744','lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug interactions prolonging the half-life of glucocorticoids via cytochrome P450 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• BMI (high) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Daily caloric intake (&gt;30 kcal/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including dexamethasone, may cause GI effects, including <b>peptic ulcer</b> (with possible perforation and hemorrhage), dyspepsia, gastritis, <b>abdominal distention</b>, and <b>ulcerative esophagitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>). Meta-analyses suggest that glucocorticoid monotherapy carries little to no risk of peptic ulcer disease in the general population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-23947590'])">Ref</a></span>). Studies have demonstrated an increased risk of focal small bowel perforation in infants with low birth weight receiving dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10645522','lexi-content-ref-11503101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10645522','lexi-content-ref-11503101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; glucocorticoids inhibit gastroprotective prostaglandin synthesis and reduce gastric mucus and bicarbonate secretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23919213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23919213'])">Ref</a></span>). Glucocorticoid immunosuppressive effects may prevent wound healing as well as mask GI signs and symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24833682'])">Ref</a></span>). Focal small bowel perforation is thought to be due to segmental degeneration of the muscularis externa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10645522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10645522'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (equivalent to methylprednisolone ≥4 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096497'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21357821','lexi-content-ref-23919213','lexi-content-ref-11390328','lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21357821','lexi-content-ref-23919213','lexi-content-ref-11390328','lexi-content-ref-24833682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized (but not ambulatory) patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24833682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infants with low birth weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11194544','lexi-content-ref-10645522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11194544','lexi-content-ref-10645522'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent glucocorticoid users (7 to 28 days) versus remote or nonusers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096497'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including dexamethasone, may provoke new-onset <b>hyperglycemia </b>in patients without a history of diabetes and may cause an <b>exacerbation of diabetes mellitus</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580','lexi-content-ref-26240704'])">Ref</a></span>). Glucose levels have been noted to increase 68% above baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704'])">Ref</a></span>). Certain patient populations (eg, transplant, cancer, chronic rheumatologic conditions) are at particular risk due to medication combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580'])">Ref</a></span>). Resolution may occur within 24 to 36 hours after dexamethasone discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28836444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; increased insulin resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580','lexi-content-ref-22187441','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580','lexi-content-ref-22187441','lexi-content-ref-26240704'])">Ref</a></span>). May also interfere with insulin signaling by direct effects on the insulin receptor and the glucose transporter and may promote gluconeogenesis via liver stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704','lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704','lexi-content-ref-28836444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704','lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704','lexi-content-ref-28836444'])">Ref</a></span>). Rapid onset of steroid-induced hyperglycemia occurred within 2 days after initiation of glucocorticoids with a peak in the late afternoon following daily dosing in the morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23298665','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23298665','lexi-content-ref-26240704'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose and type of glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Divided versus once-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV and oral routes of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• BMI &gt;25 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• African American or Hispanic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• eGFR &lt;40 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HbA<sub>1c</sub> ≥6% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of gestational diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of mycophenolate mofetil and calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of impaired fasting glucose or impaired glucose tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients receiving palliative care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22583383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22583383'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including dexamethasone, have immunosuppressive and anti-inflammatory effects that are reversible with discontinuation. <b>Infection</b> may occur after prolonged use, including <i>Pneumocystis jirovecii pneumonia</i> (PJP), herpes zoster, tuberculosis, and other more common bacterial infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; related to pharmacologic action (ie, multiple activities on cell macrophage production and differentiation, inhibition of T-cell activation, and effects on dendritic cells) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8239251','lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8239251','lexi-content-ref-26611557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in one study, the median duration of glucocorticoid use prior to PJP diagnosis was 12 weeks but also occurred earlier or later in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8538233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8538233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose and longer duration of glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-23137579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-23137579'])">Ref</a></span>); however, may also increase risk at lower doses (eg, ≤5 mg/day of prednisone or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32956604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32956604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications (immunosuppressive) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rheumatoid arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137579'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Interstitial lung disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902','lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902','lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Male (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low performance status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuromuscular and skeletal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoid (including dexamethasone)-induced neuromuscular and skeletal effects can take the form of various pathologies in patients ranging from <b>osteoporosis</b> and <b>vertebral compression fracture</b> to <b>myopathy</b> to <b>osteonecrosis </b>in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>). Glucocorticoid use is the most common cause of secondary osteoporosis; may be underrecognized and undertreated due to underestimation of risk in this patient population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17982350','lexi-content-ref-26509049','lexi-content-ref-25905379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17982350','lexi-content-ref-26509049','lexi-content-ref-25905379'])">Ref</a></span>). Vertebral fractures are the most common glucocorticoid-related fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>). Myopathies can also occur secondary to direct skeletal muscle catabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>). Acute <b>steroid myopathy</b> is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462474'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; glucocorticoids have direct/indirect effects on bone remodeling with osteoblast recruitment decreasing and apoptosis increasing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Buckley.2017','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Buckley.2017','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>). Myopathies or <b>myasthenia</b> result from reductions in protein synthesis and protein catabolism, which can manifest as proximal muscle weakness and atrophy in the upper and lower extremities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; vertebral fracture risk is increased within 3 months of initiation and peaks at 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-related risks:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cumulative dose of glucocorticoids prednisone &gt;5 g or equivalent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Children receiving ≥4 courses of glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17332238','lexi-content-ref-12733732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17332238','lexi-content-ref-12733732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prednisone ≥2.5 mg to 7.5 mg daily or equivalent for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Myopathy may occur at prednisone doses ≥10 mg daily or equivalent, with higher doses potentiating more of a rapid onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Fluorinated glucocorticoid preparations (eg, dexamethasone, betamethasone, triamcinolone) have a higher risk of myopathies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">General fracture risks:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• BMI &lt;18.5 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bone mineral T score below -1.5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Endocrine disorders (eg, hypogonadism, hyper- or hypoparathyroidism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Excess alcohol use (&gt;2 units/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of falls (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Malabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Menopause and duration of menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• White race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients with cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Previous fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Underlying inflammatory condition in all ages (eg, inflammatory bowel disease, rheumatoid arthritis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-17332238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-17332238'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Glucocorticoid (including dexamethasone)-induced ocular effects may include <b>increased intraocular pressure</b> (IOP), <b>glaucoma </b>(open-angle), and <b>subcapsular posterior</b>
<b>cataract</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15932528','lexi-content-ref-28924342','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15932528','lexi-content-ref-28924342','lexi-content-ref-21757964'])">Ref</a></span>). Cataracts may persist after discontinuation of glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21666852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21666852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; Glucocorticoids can induce cataracts by covalently bonding to lens proteins, causing destabilization of the protein structure, and oxidative changes leading to cataracts formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9464184','lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9464184','lexi-content-ref-28924342'])">Ref</a></span>). There are various proposed mechanisms of IOP contributing to glaucoma, including accumulation of polymerized glycosaminoglycans in the trabecular meshwork, producing edema and increasing outflow resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924342'])">Ref</a></span>). Another mechanism may include inhibition of phagocytic endothelial cells, leading to accumulation of aqueous debris (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924342'])">Ref</a></span>). Glucocorticoids can also alter the trabecular meshwork causing an increase in nuclear size and DNA content (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>). In addition, they can decrease the synthesis of prostaglandins which regulate the aqueous outflow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; cataracts may occur at least 1 year after initiation of chronic glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17900234','lexi-content-ref-3541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17900234','lexi-content-ref-3541262'])">Ref</a></span>). IOP may occur at 4 years or more after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Topical &gt; Systemic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of open-angle glaucoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type I diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17900234','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17900234','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High myopia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pseudophakia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior vitrectomies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Connective tissue disease and sex (eg, rheumatoid arthritis in males) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients or age &lt;6 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Angle recessive glaucoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8015706"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Some reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for dexamethasone.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiomegaly, circulatory shock, edema, embolism (fat), heart failure (in susceptible patients), hypertension, myocardial rupture (after recent myocardial infarction), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, allergic dermatitis, alopecia, atrophic striae, diaphoresis, ecchymoses, erythema of skin, facial erythema, fragile skin, hyperpigmentation, hypertrichosis, hypopigmentation, inadvertent suppression of skin test reaction, perianal skin irritation (itching, burning, tingling; following rapid IV injection; more common in females, with higher doses; sudden onset with resolution in &lt;1 minute) (Allan 1986; Neff 2002; Perron 2003; Singh 2011), skin atrophy, skin rash, subcutaneous atrophy, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium, fluid retention, growth suppression (children), hirsutism, hypokalemic alkalosis, menstrual disease, negative nitrogen balance (due to protein catabolism), sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hiccups, increased appetite, nausea, pancreatitis, pruritus ani (following IV injection)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Defective spermatogenesis (increased or decreased), glycosuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Kaposi sarcoma (Goedert 2002), petechia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatomegaly, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sterile abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Postinjection flare (intra-articular use)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amyotrophy, emotional lability, euphoria, headache, increased intracranial pressure, intracranial hypertension (idiopathic; usually following discontinuation), malaise, myasthenia, neuritis, neuropathy, paresthesia, personality changes, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Charcot arthropathy, rupture of tendon</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Exophthalmos</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertrophic cardiomyopathy (premature infants) (Kale 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenal suppression (tertiary) (Dineen 2019), Cushing syndrome (iatrogenic) (Hopkins 2005), cushingoid appearance (Hopkins 2005), exacerbation of diabetes mellitus (Tamez-Pérez 2015), hyperglycemia (Tamez-Pérez 2015), impaired glucose tolerance (Tamez-Pérez 2015), moon face (Hopkins 2005), redistribution of body fat (Hopkins 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (Liu 2013), intestinal perforation (Gordon 1999, Gordon 2001), peptic ulcer (with possible perforation and hemorrhage) (Liu 2013), ulcerative esophagitis (Liu 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor lysis syndrome (Chanimov 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (Youssef 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Apathy (Ciriaco 2013, Warrington 2006), depression (Ciriaco 2013, Warrington 2006), psychiatric disturbance (including agitation, anxiety, distractibility, euphoria, fear, hypomania, insomnia, irritability, labile mood, lethargy, pressured speech, restlessness, tearfulness) (Ciriaco 2013, Warrington 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Buckley 2018), myopathy (Liu 2013), osteonecrosis (femoral and humoral heads) (Liu 2013), osteoporosis (Buckley 2018), steroid myopathy (Haran 2018), vertebral compression fracture (Buckley 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma (Phulke 2017), increased intraocular pressure (Phulke 2017), subcapsular posterior cataract (Urban 1986)</p></div>
<div class="block coi drugH1Div" id="F8015703"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to dexamethasone or any component of the formulation; systemic fungal infections</p></div>
<div class="block war drugH1Div" id="F8015704"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal axis, particularly in younger children.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Dexamethasone does not provide any mineralocorticoid activity in adrenal insufficiency (may be employed as a single dose while cortisol assays are performed). Hydrocortisone is the preferred treatment of chronic primary adrenal insufficiency and adrenal crisis (ES [Bornstein 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Monitor BP. Use with caution following acute myocardial infarction; corticosteroids have been associated with myocardial rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess, or other pyogenic infection) due to GI perforation risk. Signs of GI perforation may be masked in patients receiving corticosteroid therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone. High-dose corticosteroids should not be used for the management of head injury (BTF [Carney 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B: Reactivation may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Pheochromocytoma crisis (may be fatal) has been reported after administration of systemic corticosteroids. Consider the risk of pheochromocytoma crisis in patients with suspected or confirmed pheochromocytoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma renal crisis incidence has been observed with corticosteroid use. Monitor BP and renal function in patients with systemic sclerosis treated with corticosteroids (EULAR [Kowal-Bielecka 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of corticosteroids. Non-live or inactivated vaccines may be administered, although the response cannot be predicted.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients with the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfite: Some products may contain sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylaxis and life-threatening or less severe asthmatic episodes in susceptible patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular injection: May produce systemic as well as local effects. Appropriate examination of any joint fluid present is necessary to exclude a septic process. Avoid injection into an infected site. Do not inject into unstable joints. Patients should not overuse joints in which symptomatic benefit has been obtained as long as the inflammatory process remains active. Frequent intra-articular injection may result in damage to joint tissues.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878731"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In premature neonates, the use of high-dose dexamethasone (approximately &gt;0.5 mg/kg/day) for the prevention or treatment of bronchopulmonary dysplasia has been associated with adverse neurodevelopmental outcomes, including higher rates of cerebral palsy without additional clinical benefit over lower doses; current data do not support use of high doses; further studies are needed (Watterberg 2010).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults, including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F8016329"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">dexAMETHasone Intensol: 1 mg/mL (30 mL) [contains alcohol, usp; unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Elixir, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/5 mL (237 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection, as sodium phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ReadySharp dexAMETHasone: 10 mg/mL [DSC] [contains benzyl alcohol, sodium sulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TopiDex: 10 mg/mL [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection, as sodium phosphate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Active Injection D: 10 mg/mL [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DoubleDex: 10 mg/mL</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">MAS Care-Pak: 10 mg/mL</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/5 mL (240 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/mL (1 mL); 20 mg/5 mL (5 mL); 120 mg/30 mL (30 mL); 10 mg/mL (1 mL); 100 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium phosphate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/mL (1 mL); 10 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as sodium phosphate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Decadron: 0.5 mg [DSC] [scored; contains fd&amp;c yellow #5 (tartrazine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Decadron: 0.75 mg [DSC] [scored; contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Decadron: 4 mg [DSC], 6 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemady: 20 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dexabliss: 1.5 MG (39) (39 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DexPak 10 Day: 1.5 mg (35 ea [DSC]) [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DexPak 13 Day: 1.5 mg (51 ea [DSC]) [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DexPak 6 Day: 1.5 mg (21 ea [DSC]) [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dxevo 11-Day: 1.5 mg (39 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dxevo 11-Day: 1.5 mg (39 ea [DSC]) [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HiDex 6-Day: 1.5 mg (21 ea) [scored; contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TaperDex 12-Day: 1.5 mg (49 ea) [contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TaperDex 6-Day: 1.5 mg (21 ea) [scored; contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TaperDex 6-Day: 1.5 mg (21 ea) [scored; contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TaperDex 7-Day: 1.5 mg (27 ea) [scored; contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZCORT 7-Day: 1.5 mg (25 ea [DSC]) [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 mg (21 ea, 35 ea, 51 ea)</p></div>
<div class="block geq drugH1Div" id="F8015651"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8016331"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (dexAMETHasone Intensol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $1.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Elixir</b> (dexAMETHasone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/5 mL (per mL): $0.11 - $1.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (DoubleDex Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per each): $598.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (MAS Care-Pak Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per each): $605.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (dexAMETHasone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/5 mL (per mL): $0.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (dexAMETHasone Sod Phosphate PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $2.10 - $9.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (dexAMETHasone Sodium Phosphate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $0.93 - $3.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $1.49 - $1.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/5 mL (per mL): $0.21 - $1.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $0.48 - $1.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg/30 mL (per mL): $0.39 - $1.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (dexAMETHasone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5MG (21) (per each): $8.06 - $8.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5MG (35) (per each): $8.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5MG (51) (per each): $8.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (HiDex 6-Day Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5MG (21) (per each): $33.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (TaperDex 12-Day Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5MG (49) (per each): $5.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (TaperDex 6-Day Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $10.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5MG (21) (per each): $10.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (TaperDex 7-Day Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5MG (27) (per each): $8.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (dexAMETHasone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.14 - $0.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75 mg (per each): $0.25 - $0.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.30 - $0.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $0.48 - $15.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.55 - $0.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $1.19 - $1.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $1.78 - $1.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Hemady Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $32.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869110"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Elixir, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/5 mL (100 ea, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/mL (5 mL); 10 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 0.75 mg, 2 mg, 4 mg</p></div>
<div class="block adm drugH1Div" id="F8016306"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with meals to help prevent GI upset. If appropriate, may administer antacids between meals to help prevent peptic ulcers.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral concentrate: Use only the calibrated dropper provided. Draw dose into dropper; squeeze dropper contents into a liquid or semi-solid food (water, juice, soda or soda-like beverage, applesauce, pudding). Gently stir for a few seconds. Administer the entire mixture immediately. Do not store for future use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> May administer 4 mg/mL or 10 mg/mL concentration undiluted over ≥1 minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gahart.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gahart.1'])">Ref</a></span>) or infuse by IVPB over 5 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2871314','lexi-content-ref-12075649','lexi-content-ref-12944454','lexi-content-ref-Raajasekar.1','lexi-content-ref-Singh.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2871314','lexi-content-ref-12075649','lexi-content-ref-12944454','lexi-content-ref-Raajasekar.1','lexi-content-ref-Singh.2011'])">Ref</a></span>). Rapid administration of dexamethasone may be associated with perineal irritation (especially with higher doses); consider further dilution and slower administration by IVPB to avoid perineal irritation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2871314','lexi-content-ref-12075649','lexi-content-ref-12944454','lexi-content-ref-Singh.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2871314','lexi-content-ref-12075649','lexi-content-ref-12944454','lexi-content-ref-Singh.2011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer 4 mg/mL or 10 mg/mL concentration by deep IM injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-articular or soft tissue injection: Note:</b> Dexamethasone <b>sodium phosphate</b> (a short-acting solution) is the only formulation available for intra-articular or soft tissue injections in the United States or Canada. Other glucocorticoids, such as triamcinolone acetonide or methylprednisolone acetate, are used more commonly for intra-articular or soft tissue injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7727555','lexi-content-ref-Roberts.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7727555','lexi-content-ref-Roberts.1'])">Ref</a></span>). Refer to product-specific labeling for further details.</p>
<p style="text-indent:-2em;margin-left:4em;">Intra-articular: Administer into affected joint.</p>
<p style="text-indent:-2em;margin-left:4em;">Soft tissue: Administer into affected tissue.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intralesional injection:</b>
<b>Note:</b> Dexamethasone <b>sodium phosphate</b> (a short-acting solution) is the only formulation available for intralesional injections in the United States or Canada. Another glucocorticoid, triamcinolone acetonide, is used more commonly for intralesional injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mathes.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mathes.1'])">Ref</a></span>). Refer to product-specific labeling for further details.</p>
<p style="text-indent:-2em;margin-left:4em;">Intralesional: Administer into affected area.</p></div>
<div class="block admp drugH1Div" id="F52614335"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food or milk to decrease GI adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Use preservative-free dosage forms in neonates.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: May administer 4 mg/mL or 10 mg/mL undiluted.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: May administer as undiluted solution (4 mg/mL or 10 mg/mL) slow IV push, usually over 1 to 4 minutes; rapid administration is associated with perineal discomfort (burning, tingling) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2871314','lexi-content-ref-12075649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2871314','lexi-content-ref-12075649'])">Ref</a></span>); may consider further dilution of high doses and administration by IV intermittent infusion over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2871314','lexi-content-ref-9787142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2871314','lexi-content-ref-9787142'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F8015652"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, IV, or IM injection:</b> Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including those of allergic, hematologic (eg, immune thrombocytopenia), dermatologic, neoplastic (leukemias, lymphomas, and multiple myeloma), rheumatic, autoimmune, nervous system, renal, and respiratory origin; primary or secondary adrenocorticoid deficiency (not first line); management of shock, cerebral edema, and as a diagnostic agent.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Intra-articular or soft tissue injection: </b>As adjunctive therapy for short-term administration in synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, and posttraumatic osteoarthritis.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Intralesional injection: </b>Keloids; localized hypertrophic, infiltrated, inflammatory lesions of lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis); discoid lupus erythematosus; necrobiosis lipoidica diabeticorum; alopecia areata; cystic tumors of an aponeurosis or tendon (ganglia).</p></div>
<div class="block off-label drugH1Div" id="F25475108"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute mountain sickness/high-altitude cerebral edema; Acute respiratory distress syndrome, moderate to severe; Antiemetic regimens: Chemotherapy-associated nausea and vomiting, prevention; Antiemetic regimens: Postoperative nausea and vomiting, prevention; Antiemetic regimens: Radiation therapy-associated nausea and vomiting, prevention; Asthma, acute exacerbation; Cancer-related cachexia; Cancer-related pain, advanced cancer, adjuvant therapy; COVID-19, hospitalized patients; Fetal lung maturation, acceleration of; Meningitis (bacterial), prevention of neurologic complications; Migraine, recurrence prevention</p></div>
<div class="block mst drugH1Div" id="F8015647"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DexAMETHasone may be confused with desoximetasone, dexmedeTOMIDine, dextroamphetamine</p>
<p style="text-indent:-2em;margin-left:4em;">Decadron may be confused with Percodan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8015710"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F8015711"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib.  Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Corticosteroids (Systemic) may diminish the therapeutic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of systemic corticosteroid is reduced. Corticosteroids (Systemic) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May increase the serum concentration of DexAMETHasone (Systemic). Management: Reduce dexamethasone dose 50% with aprepitant. Aprepitant labeling incorporates this recommendation into the dose provided for dexamethasone; further reduction is not necessary. No dose adjustment may be needed with single, low-dose aprepitant for PONV.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib.  Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy.  Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of DexAMETHasone (Systemic). DexAMETHasone (Systemic) may decrease the serum concentration of Cobicistat. Management: Consider an alternative corticosteroid. Monitor patients receiving this combination closely for evidence of diminished response to the antiviral regimen as well as increased dexamethasone effects and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Corticosteroids (Systemic) may diminish the diagnostic effect of Cosyntropin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of DexAMETHasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of DexAMETHasone (Systemic). Management: Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced dexamethasone efficacy. Consider avoiding this combination when treating life threatening conditions (ie, multiple myeloma).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DexAMETHasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DexAMETHasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: DexAMETHasone (Systemic) may decrease the serum concentration of Delavirdine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: The use of deucravacitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: DexAMETHasone (Systemic) may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative corticosteroid.  Monitor patients receiving these agents in combination for diminished antiviral response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): May decrease the serum concentration of DexAMETHasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Etrasimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Filgotinib.  Management: Coadministration of filgotinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: DexAMETHasone (Systemic) may decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: May increase the serum concentration of DexAMETHasone (Systemic). Management: Reduce the dexamethasone dose 50% when coadministered with aprepitant. Aprepitant prescribing information incorporates this recommendation into the dose provided for dexamethasone; further reduction is not necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: May increase the serum concentration of DexAMETHasone (Systemic). Management: Decrease dexamethasone doses to 12 mg on day 1, and if needed based on the emetic potential of the regimen, 8 mg daily on days 2 to 4 of chemotherapy when administered with fosnetupitant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of DexAMETHasone (Systemic). DexAMETHasone (Systemic) may decrease the serum concentration of Fosphenytoin. DexAMETHasone (Systemic) may increase the serum concentration of Fosphenytoin. Management: Consider dexamethasone dose increases when combined with fosphenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely, both increased and decreased phenytoin levels have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Corticosteroids (Systemic) may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: DexAMETHasone (Systemic) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with dexamethasone when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor clinical response closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).  Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: DexAMETHasone (Systemic) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: DexAMETHasone (Systemic) may enhance the thrombogenic effect of Lenalidomide.  Management: Consider using venous thromboembolism prophylaxis (eg, low-molecular weight heparin or warfarin [INR 2.0-3.0]) in patients with multiple myeloma who are receiving lenalidomide and dexamethasone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: DexAMETHasone (Systemic) may decrease the serum concentration of Lopinavir.  Management: Consider alternative corticosteroids for coadministration with lopinavir/ritonavir due to the potential for dexamethasone to decrease lopinavir/ritonavir efficacy and result in the development of resistance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate.  Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Corticosteroids (Systemic) may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: May increase the serum concentration of DexAMETHasone (Systemic). Management: Decrease dexamethasone doses to 12 mg on day 1, and if needed based on the emetic potential of the regimen, 8 mg daily on days 2 to 4 of chemotherapy when administered with netupitant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of DexAMETHasone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of DexAMETHasone (Systemic). DexAMETHasone (Systemic) may decrease the serum concentration of Phenytoin. DexAMETHasone (Systemic) may increase the serum concentration of Phenytoin. Management: Consider dexamethasone dose increases when combined with phenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely when combined with dexamethasone, both increased and decreased phenytoin levels have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: DexAMETHasone (Systemic) may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: DexAMETHasone (Systemic) may decrease the serum concentration of Saquinavir.  Management: Consider alternatives to this combination if possible, due to the potential for decreased saquinavir/ritonavir therapeutic effect and the potential development of resistance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: DexAMETHasone (Systemic) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: DexAMETHasone (Systemic) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: DexAMETHasone (Systemic) may enhance the dermatologic adverse effect of Thalidomide. DexAMETHasone (Systemic) may enhance the thrombogenic effect of Thalidomide.  Management: Consider using venous thromboembolism prophylaxis (eg, low-molecular-weight heparin or warfarin [INR 2.0 to 3.0]) in patients with multiple myeloma receiving both thalidomide and dexamethasone. Monitor for increased dermatologic adverse effects (eg, rash)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib.  Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: DexAMETHasone (Systemic) may decrease the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54978264"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The manufacturer's labeling for use of dexamethasone as part of combination therapy for multiple myeloma recommends pregnancy testing prior to use in patients who may become pregnant. Patients who may become pregnant should use effective contraception during therapy and for at least 1 month after the last dexamethasone dose. Consult individual monographs for additional information related to pregnancy testing and contraception when combination therapy is used for multiple myeloma.</p>
<p style="text-indent:0em;margin-top:2em;">Dexamethasone may alter the motility of and number of spermatozoa.</p></div>
<div class="block pri drugH1Div" id="F8015699"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dexamethasone crosses the placenta (Brownfoot 2013); and is partially metabolized by placental enzymes to an inactive metabolite (Murphy 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids during pregnancy; monitor.</p>
<p style="text-indent:0em;margin-top:2em;">Dexamethasone is classified as a fluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders, nonfluorinated corticosteroids (eg, prednisone) are preferred. Chronic high doses should be avoided for the treatment of maternal disease (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Use of the overnight dexamethasone 1 mg suppression test for Cushing syndrome is not recommended during pregnancy due to the increased risk of false positives. In addition, dexamethasone is generally avoided for the treatment of pregnant patients with adrenal insufficiency (ES [Nieman 2008]; ESE [Luger 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Antenatal corticosteroid administration promotes fetal lung maturity and is associated with the reduction of intraventricular hemorrhage, necrotizing enterocolitis, neonatal mortality, and respiratory distress syndrome. A single course of dexamethasone is recommended for patients between 24 0/7 and 33 6/7 weeks' gestation who are at risk of delivering within 7 days. This recommendation includes those with ruptured membranes or multiple gestations. A single course of dexamethasone may be considered for patients beginning at 22 0/7 weeks' gestation who are at risk of delivering within 7 days, in consultation with the family regarding resuscitation. In addition, a single course of dexamethasone may be given to patients between 34 0/7 weeks and 36 6/7 weeks who are at risk of preterm delivery within 7 days and who have not previously received corticosteroids if induction or delivery will proceed ≥24 hours and ≤7 days; delivery should not be delayed for administration of antenatal corticosteroids. Use of concomitant tocolytics is not currently recommended and administration of late preterm corticosteroids has not been evaluated in patients with intrauterine infection, multiple gestations, pregestational diabetes, or patients who delivered previously by cesarean section at term. Multiple repeat courses are not recommended. However, in patients with pregnancies less than 34 weeks' gestation at risk for delivery within 7 days and who had a course of antenatal corticosteroids &gt;14 days prior, a single repeat course may be considered; use of a repeat course in patients with preterm prelabor rupture of membranes is controversial (ACOG 2016; ACOG 2017; ACOG 2020; ACOG 2022a).</p>
<p style="text-indent:0em;margin-top:2em;">Dexamethasone is used off label in the management of COVID-19. In general, the treatment of COVID-19 during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process. Dexamethasone is recommended for hospitalized pregnant patients with COVID-19 if indicated (NIH 2023). In patients who do not require dexamethasone for fetal lung maturity, or in those who have already completed a course of dexamethasone to enhance fetal lung development, treatment recommendations are available using alternative corticosteroids which have more limited placental transfer and may provide less fetal risk. Suggested treatment algorithms are available for pregnant patients with severe or critical COVID-19 requiring corticosteroids (Saad 2020; Teelucksingh 2022). The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients (ACOG 2023). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Some products contain alcohol, benzyl alcohol or sodium sulfite; use of preservative-free or alternative formulations in pregnancy is recommended.</p></div>
<div class="block brc drugH1Div" id="F8015702"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids are present in breast milk; information specific to dexamethasone has not been located.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production).</p>
<p style="text-indent:-2em;margin-left:2em;">Single doses of dexamethasone are considered compatible with breastfeeding; information related to prolonged use is not available (WHO 2002). Breastfeeding can continue if dexamethasone is needed for the management of COVID-19 (NIH 2023). However, lactating patients with COVID-19 infection can transmit the virus through respiratory droplets and all precautions should be taken to avoid spreading the virus to the infant (eg, hand hygiene, mask wearing); alternatively, breast milk can be expressed and fed to the infant by someone without confirmed or suspected COVID-19 (ACOG 2023; NIH 2023). Dexamethasone is classified as a fluorinated corticosteroid. When systemic corticosteroids are needed in a lactating patient for rheumatic disorders, low doses of nonfluorinated corticosteroids (eg, prednisone) are preferred (ACR [Sammaritano 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, some manufacturers recommend a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. If there is concern about exposure to the infant, some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding in order to decrease potential exposure to the breastfed infant (based on a study using prednisolone) (Leachman 2006; Makol 2011; Ost 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer's labeling for use of dexamethasone as part of combination therapy for multiple myeloma recommends breastfeeding be discontinued during therapy and for 2 weeks after the last dexamethasone dose.</p></div>
<div class="block dic drugH1Div" id="F8015756"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with meals to decrease GI upset. May need diet with increased potassium, pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus.</p></div>
<div class="block mop drugH1Div" id="F8016312"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hb, occult blood loss, BP, serum potassium, blood glucose, creatine kinase (if symptoms of myopathy occur), bone mineral density; intraocular pressure with systemic use &gt;6 weeks; consider routine eye exams with chronic use; weight and height in children; hypothalamic-pituitary-adrenal axis suppression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Oncology patients:</i> Evaluate pregnancy status (in females of reproductive potential when receiving for multiple myeloma treatment). The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F8015721"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dexamethasone is a long-acting corticosteroid with minimal sodium-retaining potential. It decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response. Dexamethasone induces apoptosis in multiple myeloma cells. Dexamethasone's mechanism of antiemetic activity is unknown.</p></div>
<div class="block phk drugH1Div" id="F8015724"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: Rapid.</p>
<p style="text-indent:-2em;margin-left:4em;">Immune thrombocytopenia: Oral: Initial response: 2 to 14 days; Peak response: 4 to 28 days (Neunert 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IV: Short.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: 61% to 86% (Czock 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Extremely low birth-weight infants with BPD: 9.26 ± 3.34 hours (range: 5.85 to 16.1 hours) (Charles 1993).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 months to 16 years: 4.34 ± 4.14 hours (range: 2.33 to 9.54 hours) (Richter 1983).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral: 4 ± 0.9 hours (Czock 2005); IV: ~1 to 5 hours (Hochhaus 2001; Miyabo 1981; Rohdewald 1987; Tóth 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 1 to 2 hours (Czock 2005); IM: ~30 to 120 minutes (Egerman 1997; Hochhaus 2001); IV: 5 to 10 minutes (free dexamethasone) (Miyabo 1981; Rohdewald 1987).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~10%) (Duggan 1975; Miyabo 1981).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961968"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Arcodexan | Decadron | Dexa Scheroson | Dexamed | Dexamethasone | Dexona | Mephamesone | Minims dexamethasone | Ozurdex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexalaf | Dexalergin | Dexameral | Dexametasona | Dexametasona dunca | Dexametasona fabra | Dexametasona larjan | Dexametasona richet | Dexamfor | Dexatotal | Duo decadron | Egosona | Fada dexametasona | Lormine | Nexadron | Ozurdex | Rupedex</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dexamethason | Dexamethason hcs | Fortecortin | Infectodexakrupp | Monodex | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dexamethasone | Dexamethasone s/ph | Dexmethsone | Ozurdex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">D-Cort | Decason | Dexa | Dexam | Dexamet | Dexamethason | Dexamin | Dexan | Dexcor | Dexon | Dexonex | Dextason | Dextor | Gludex | Meradexon | Metadaxan | Odeson | Oradexon | Ordex | Redexon | Rednisone | Sonexa | Steron</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aacidexam | Decadron | Dexamethasone organon | Dexamethasone viatris | Monofree dexamethason | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexafree | Dexamethason Krka | Ozurdex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acetazona | Bexeton | Cortitop | Decadron | Decadronal | Decazol | Deflaren | Dexaden | Dexaflan | Dexaglos | Dexametasona | Dexametazona | Dexametonal | Dexamex | Dexan | Dexanil | Dexason | Dexazen | Dexazona | Dexmene | Duo decadron | Koidexa | Metadex | Neodex | Ozurdex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexacortin | Dexamethason Galepharm | Fortecortin | Mephameson | Millicorten | Ozurdex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Lodsterod</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cortyk | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dexamethasone | Yi ke tie</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alfalyl | Balancort | Decadron | Decadronal | Deltafluorene | Dexalyl | Dexametasona | Duo decadron | Myecort | Neofordex | Oradexon | Ozurdex | Tavesona</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dexamethazon | Fortecortin | Ozurdex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Auxiloson | Cortidexason | Dexa | Dexa Clinit | Dexa loscon mono | Dexa sine | Dexa sine se | Dexaflam | Dexafluid sine | Dexaliquid geriasan | Dexamethason Acis | Dexamethason galen | Dexamethason jenapharm | Dexamethason MP | Dexamethason tad | Dexamonozon | Fortecortin | Infectodexakrupp | Lipotalon | Monodex | Ozurdex | Solutio Cordes Dexa N</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alin | Arcodexan | Betapron | Dardex | Decadron | Dexagesic | Dexalocal | Dexametasona | Dexametasona inmenol | Dexametin | Dexona</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexametasona | Dexametazona | Duo decadron</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dexamed | Dexametason | Dexamethason | Dexamethason galen | Dexamethason Krka | Dexamethasonum | Nodexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Deltasone | Dexamethasone | Dexazone | Fortecortin | Methabiogen | Oradexon | Orazone | Ozurdex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dexafree | Dexametasona abdrug | Dexametasona krka | Fortecortin | Ozurdex</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Prednisolon f | Xsone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexametason | Dexametason Abcur | Dexamethason star | Kaarmepakkaus | Monopex | Neofordex | Ozurdex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dectancyl | Dexamethasone PCH | Dexliq | Neodex | Neofordex | Ozurdex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexacortisyl | Dexafree | Dexamethasone | Dexsol | Dropodex | Martapan | Neofordex | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Amelinor | Axium | Decadron | Decadron/Visufarma | Deksametazon Krka | Dexa dose | Dexafree | Dexaleau | Dexamethasone/Rosemont | Dexamezone | Neofordex | Oradexon | Ozurdex | Perazone | Suomi | Suomicon | Thilodexine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo dexamethasone | Cp dexa | Daxilone | Decadron | Dexamed | Dexasone | Dexatab | Dexmetha | Dexmethasone | Dexmethsone | Dexone | Euromethasone | Kovin tong | Ozurdex | Scandexon | Zotex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Deksametazon Krka | Dexamethason Krka</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dexamethasone Krka | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adrekon | Carbidu | Cellacort | Cetadexon | Corsona | Cortidex | Danasone | Decilone | Dellamethasone | Deltafluorene | Dexa-m | Dexacort | Dexamethasone | Dexanel | Dexicorta | Dexon | Diometa | Ermethasone | Etason | Faridexon | Fexadron | Fortecortin | Grathazon | Hopamethasone | Ifidex | Indexon | Kalmethasone | Lanadexon | Licodexon | Mecoxon | Mediamethasone | Megadex | Molacort | Nufadex m | Omedexon | Oradexon | Pidexon | Prodexon | Pycameth | Pyradexon | Scandexon | Syndexa | Zecaxon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexafree | Dexsol | Dropodex | Ozurdex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dexacort | Dexamethazone</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adesone | Auradex | Biodexone | Cortidex | Deca forte | Decdak st | Decdan | Deexa | Deksa | Demson | Dexacip | Dexacron | Dexagee | Dexamag | Dexamethasone | Dexamine | Dexane | Dexasone | Dexinga | Dexona | Dicorsone | Idizone | Mycidex | Randexa | Stedex | Wymesone | Zuvidexa | Zydexa</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awzaron | Dixsoon | Furadex | Ipisone | Kindixone</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Desadoc | Eta cortilen | Oftacortal | Soldesam | Tamesad | Usoldec | Visucortex</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexamed</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Carulon | Corson | Daidoron | Decadron | Dectan chugai | Deron s | Dethamedin | Dexa | Dexa ferosone | Dexa Scheroson | Dexamethasone asahi kasei | Dexamethasone fuso | Dexamethasone isei | Dexamethasone kowa | Dexamethasone merck hoei | Dexamethasone mitsubishi | Dexamethasone nipro | Dexamethasone organon | Dexamethasone s.s. seiyaku | Dexamethasone sawai | Dexamethasone showa | Dexamethasone taisho | Dexamethasone taiyo | Dexamethasone tobishi | Dexamethasone towa | Dexasone | Donray | Elixirmethasone | Lenadex | Limethason | Limethason gc | Loverine | Metasolon | Mitasone | Orgadrone | Santeson | Sawasone | Solcort</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dexafil | Dexasone | Omnidex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Deltafluorene | Dexa | Dexa Scheroson | Dexacotisil | Dexamethasone bkw | Dexan | Dexasolone | Dexasone | Dextason | Limethason | Megadexa | Oradexon | Ozurdex | Samnam dexamethasone | Sindexa | Sinil dexamethasone | Yuhan dexamethasone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexafree | Dexsol | Ozurdex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexafree | Dexamed | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dexa Edo | Dexa sine se | Dexafree | Dexamed | Dexamethason | Dexamethason Krka | Dexason | Dexona | Monodex | Nodexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aacidexam | Fortecortin | Monofree Dexamethason | Oradexon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dectancyl | Dexamethason | Dexason | Maxidex | Nodexon | Orlixon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexafree | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adrecort | Alin | Alin depot | Alleffective | Benimex | Decadron | Decadronal | Decorex | Dexagrin | Dexametasona | Dibasona | Etacortilen | Metax | Migradexan | Neptonax | Oradexon | Ozurdex | Wiserdex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cortidax | Decadron | Decan | Detasone | Dexa | Dexalone | Dexamethasone | Dexasone | Dexin | Dextrasone | Erladexone | Mexasone | Minims dexamethasone | Ozurdex | Roximeth | Vextasone</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Alapharm dexamethasone | Bhudex | Bleor dexamethasone | Climax dexamethasone | Delisa | Dexacee | Dexacure | Global young dexamethasone | Greenlife dexamethasone | Hydexa | Jamdexa | Kris dexamethasone | Lifeline dexamethasone | Liricon dexamethasone | Macdexa | Marley dexamethasone | Medexone | Nci odia | Nkoyo dexamethasone | P one dexamethasone | Rebok dexamethasone | Rich dexa | Ricnos dexamethasone | Sivodexa | Surelife dexamethasone | Talidexa | Timec dexamethasone | Updexa | Xasten | Yellow dexamethasone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexamethason | Dexamethason Apotex | Dexamethason CF | Dexamethason PCH | Monofree dexamethason | Oradexon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexa sine | Dexacortin | Dexagalen | Dexamethason | Dexamethason Abcur | Dexamethason jenapharm | Dexamethasone Krka | Dexaton | Fortecortin | Monopex | Neofordex | Ozurdex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexmethsone | Ozurdex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Branxona | Decadron | Decorten | Desazona | Dexa find | Dexacler | Dexacort | Dexafar | Dexaflam elixir | Dexalab | Dexaler | Dexaluxor | Dexam | Dexamark | Dexamedix | Dexametan | Dexametasona | Dexamizan | Dexaplus | Dexasona | Dexators | Dexavet | Dexpharm | Dxa four | Lipdex | Medasonil | Medicort | Oradexon | Quillacort | Sedexxa | Terbometasona | Tetracort</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Decilone | Dexacort | Dexamethason | Dexamethasone Gamot | Dexat | Dexone | Drenex | Impodex | Inflam | Oradexon | Ozurdex | Sterasone | Sydencort | Vexamet</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aldron | Decadron | Decasone | Dexadrin | Dexadron | Dexamethasone | Dexason | Dexawal | Duo decadron | Fortecortin | Irzamethasone | Kanadex | Maxidex | Oradexon | Shirodex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Demezon | Dexafree | Dexamecortin | Dexamethason | Dexamethasone Krka | Dexason | Ozurdex | Pabi-dexamethason</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Active injection kit d | Ak-Dex | Decadron | Dexabliss | Dexamethasone | Dexamethasone Intensol | Dexpak jr | Dmt suik | Dxevo | Hemady | Locort | Mas care pak | Readysharp dexamethasone | Taperdex | Topidex | Zcort | Zema-Pak | Zodex | Zonacort</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Dexafree | Dexametasona kabi | Dexametasona krka | Dexamethasone | Fortecortin | Ozurdex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ciprocort a nf | Decadron | Dexametasona celsius | Dexametasona dallas | Dexametasona heisecke | Metadin d nf | Monocort | Zicacort</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Deksamet | Dexamed Phosphate | Dexazone</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dexamed | Dexametazona krka | Dexamethason | Ozurdex | Perazone</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dexamed | Dexamethason | Dexason | Dexona | Megadexan | Ozurdex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo dexamethasone | Decadron | Millicorten | Oradexon | Pms-dexamethasone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Baxil | Decadron | Dexacortal | Dexafree | Dexametason 2care4 | Dexametason Abcur | Dexametason ebb | Dexametason rosemont | Dexamethasone abacus medicine | Dexamethasone Krka | Dexamethasone paranova | Neofordex | Ozurdex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Decan | Dexalone | Dexamed | Dexasone | Dexmetha | Dextrasone | Erladexone | Mexasone | Minims dexamethasone | Ozurdex | SP Cordexa</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dexamethason | Dexamethason galen | Dexamethason jenapharm | Dexamono | Fortecortin | Ozurdex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dexametazon krka | Dexamethazon | Ozurdex</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Dxone</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">B Dexzol | B.Dexzol W | Decadron | Dexa | Dexa k | Dexa PS | Dexa-o | Dexa-p | Dexa-Win | Dexa-y | Dexamethasone | Dexamethasone T Man | Dexamo | Dexano | Dexapro | Dexasin | Dexasone | Dexatab | Dexazone | Dexone | Dexstar | Dexthasol | Dexton | Duo decadron | Limethason | Lodexa | Medexasone | Methasone | Oradexon | Ozurdex | Shor's Dexasone | Uto dexamethasone | Xasone</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dectancyl | Dexamedis Fort | Oradexon | Ozurdex | Pms-dexamethasone</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dekort | Deksalon | Dexa sine | Kordexa | Onadron | Ozurdex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ancom | Bucokon | Canalon | Deca | Decadlin | Decadolone | Decadron | Decalin | Decalon | Decan | Decans | Decaron | Decarone | Decason | Decon | Decone | Decoron | Dekesu | Demeson | Deson | Dexacortin | Dexadon | Dexadrol | Dexamethasone | Dexan | Dexaron | Dexasolen | Dexasolon | Dexason | Dexasone | Dexazone | Dexmesone | Dexon | Dexsone | Dicosheun | Dison | Dorison | Kovintong | Limeson | Medesone | Methasone | Mexasone | Neosolon | Oradexon | Ozurdex | Rocolone | Shuayan | Sundron | Teanlang | Tekuron | Ucalon | Unisone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dexafree | Dexamethason | Dexason | Dexona</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agomethasone | Axasone | Dexona | Perazone | Xsone</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Corodex | Dexametasona | Dexametasona Efa | Dinedrox</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Decalona | Decobel | Decorex | Dekort | Dexafar | Dexametasona | Dexason</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Dextazyne | Tiphadeltacil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Decadron | Minims Dexamethasone sodium phosphate | Neofordex | Oradexon | Ozurdex | Perazone</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Demson</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Dexone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35706350">
<a name="35706350"></a>Abouir K, Gosselin P, Guerrier S, et al. Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: an observational exploratory trial. <i>Clin Transl Sci.</i> 2022;15(7):1796-1804. doi:10.1111/cts.13297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/35706350/pubmed" id="35706350" target="_blank">35706350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akahoshi.1">
<a name="Akahoshi.1"></a>Akahoshi S, Hasegawa Y. Steroid-induced iatrogenic adrenal insufficiency in children: a literature review. <i>Endocrines</i>. 2020;1(2):125-137. doi:10.3390/endocrines1020012</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2871314">
<a name="2871314"></a>Allan SG, Leonard RCF. Dexamethasone antiemesis and side-effects. <i>Lancet</i>. 1986;1(8488):1035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2871314/pubmed" id="2871314" target="_blank">2871314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25288693">
<a name="25288693"></a>Allolio B. Extensive expertise in endocrinology. Adrenal crisis. <i>Eur J Endocrinol</i>. 2015;172(3):R115-R124. doi:10.1530/EJE-14-0824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25288693/pubmed" id="25288693" target="_blank">25288693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2018">
<a name="AAP.2018"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Statement of endorsement-congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. <i>Pediatrics</i>. 2010; 126(5):151. Accessed October 27, 2014. http://pediatrics.aappublications.org/content/126/5/1051.extract.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2193301">
<a name="2193301"></a>American Academy of Pediatrics Committee on Infectious Diseases. Dexamethasone Therapy for Bacterial Meningitis in Infants and Children. <i>Pediatrics.</i> 1990;86(1):130-133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2193301/pubmed" id="2193301" target="_blank">2193301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742678">
<a name="28742678"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. ACOG Committee Opinion No. 713: Antenatal corticosteroid therapy for fetal maturation. <i>Obstet Gynecol</i>. 2017;130(2):e102-e109. doi:10.1097/AOG.0000000000002237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28742678/pubmed" id="28742678" target="_blank">28742678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26695585">
<a name="26695585"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 171: Management of preterm labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi:10.1097/AOG.0000000000001711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27661654/pubmed" id="27661654" target="_blank">27661654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32080050">
<a name="32080050"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 217: Prelabor rupture of membranes.<i> Obstet Gynecol</i>. 2020;135(3):e80‐e97. doi:10.1097/AOG.0000000000003700<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32080050/pubmed" id="32080050" target="_blank">32080050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed April 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.2">
<a name="ACOG.2"></a>American College of Obstetricians and Gynecologists (ACOG). Use of antenatal corticosteroids at 22 weeks of gestation. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/09/use-of-antenatal-corticosteroids-at-22-weeks-of-gestation. Updated October 2022a. Accessed March 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published 2021. Accessed January 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8874303">
<a name="8874303"></a>Anene O, Meert KL, Uy H, Simpson P, Sarnaik AP. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. <i>Crit Care Med</i>. 1996;24(10):1666-1669.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8874303/pubmed" id="8874303" target="_blank">8874303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28938253">
<a name="28938253"></a>Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Crit Care Med</i>. 2017;45(12):2078-2088. doi: 10.1097/CCM.0000000000002737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28938253/pubmed" id="28938253" target="_blank">28938253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnold.1">
<a name="Arnold.1"></a>Arnold DM. Initial treatment of immune thrombocytopenia (ITP) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007:110, 176.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31735560">
<a name="31735560"></a>Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in <i>Lancet</i>. 2019;394(10214):2072]. <i>Lancet</i>. 2019;394(10214):2096-2107. doi:10.1016/S0140-6736(19)32556-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31735560/pubmed" id="31735560" target="_blank">31735560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2068839">
<a name="2068839"></a>Bahal N, Nahata MC. The role of corticosteroids in infants and children with bacterial meningitis. <i>DICP.</i> 1991;25(5):542-545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2068839/pubmed" id="2068839" target="_blank">2068839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23090580">
<a name="23090580"></a>Baldwin D, Apel J. Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. <i>Curr Diab Rep</i>. 2013;13(1):114-120. doi:10.1007/s11892-012-0339-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23090580/pubmed" id="23090580" target="_blank">23090580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29858690">
<a name="29858690"></a>Benghiat H, Sanghera P, Stange D, et al. Dexamethasone-related adrenal insufficiency in patients with brain and skull base tumours. <i>Support Care Cancer</i>. 2018;26(12):4031-4038. doi:10.1007/s00520-018-4264-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/29858690/pubmed" id="29858690" target="_blank">29858690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9787142">
<a name="9787142"></a>Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. <i>Blood</i>. 1998;92:3082-3089.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9787142/pubmed" id="9787142" target="_blank">9787142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17982350">
<a name="17982350"></a>Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. <i>Curr Opin Endocrinol Diabetes Obes</i>. 2007;14(6):446-450. doi:10.1097/MED.0b013e3282f15407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17982350/pubmed" id="17982350" target="_blank">17982350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bhimraj.1">
<a name="Bhimraj.1"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America (IDSA) guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#toc-5. Updated June 29, 2022. Accessed August 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15385657">
<a name="15385657"></a>Bjornson CL, Klassen TP, Williamson J, et al. A randomized trial of a single dose of oral dexamethasone for mild croup. <i>N Engl J Med.</i> 2004;351(13):1306-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15385657/pubmed" id="15385657" target="_blank">15385657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29530386">
<a name="29530386"></a>Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. <i>Diabetes Res Clin Pract</i>. 2018;139:203-220. doi:10.1016/j.diabres.2018.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/29530386/pubmed" id="29530386" target="_blank">29530386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19474430">
<a name="19474430"></a>Bornstein SR. Predisposing factors for adrenal insufficiency. <i>N Engl J Med</i>. 2009;360(22):2328-2339. doi:10.1056/NEJMra0804635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19474430/pubmed" id="19474430" target="_blank">19474430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi:10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8239251">
<a name="8239251"></a>Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. <i>Ann Intern Med</i>. 1993;119(12):1198-1208. doi:10.7326/0003-4819-119-12-199312150-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8239251/pubmed" id="8239251" target="_blank">8239251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30515225">
<a name="30515225"></a>Bowden SA, Henry R. Pediatric Adrenal insufficiency: Diagnosis, management, and new therapies. <i>Int J Pediatr</i>. 2018;2018:1739831. doi:10.1155/2018/1739831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30515225/pubmed" id="30515225" target="_blank">30515225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26509049">
<a name="26509049"></a>Briot K, Roux C. Glucocorticoid-induced osteoporosis. <i>RMD Open</i>. 2015;1(1):e000014. doi:10.1136/rmdopen-2014-000014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26509049/pubmed" id="26509049" target="_blank">26509049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23990333">
<a name="23990333"></a>Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. <i>Cochrane Database Syst Rev</i>. 2013;(8):CD006764. doi:10.1002/14651858.CD006764.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23990333/pubmed" id="23990333" target="_blank">23990333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buckley.2017">
<a name="Buckley.2017"></a>Buckley L, Fuyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Arthritis Rheumatology</i>. 2017;69(8):1521-1537.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586507">
<a name="30586507"></a>Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. <i>N Engl J Med</i>. 2018;379(26):2547-2556. doi:10.1056/NEJMcp1800214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30586507/pubmed" id="30586507" target="_blank">30586507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986133">
<a name="27986133"></a>Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. <i>J Am Acad Dermatol</i>. 2017;76(1):11-16. doi:10.1016/j.jaad.2016.02.1239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27986133/pubmed" id="27986133" target="_blank">27986133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27654000">
<a name="27654000"></a>Carney N, Totten AM, O'Reilly C, et al; Brain Trauma Foundation. Guidelines for the management of severe traumatic brain injury, fourth edition [published online September 20, 2016]. <i>Neurosurgery</i>. doi:10.1227/NEU.0000000000001432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27654000/pubmed" id="27654000" target="_blank">27654000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7727555">
<a name="7727555"></a>Centeno LM, Moore ME. Preferred intraarticular corticosteroids and associated practice: a survey of members of the American College of Rheumatology. <i>Arthritis Care Res</i>. 1994;7(3):151-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7727555/pubmed" id="7727555" target="_blank">7727555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30883663">
<a name="30883663"></a>Chang SM, Messersmith H, Ahluwalia M, et al. Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. <i>Neuro Oncol</i>. 2019;21(4):424-427. doi:10.1093/neuonc/noz034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30883663/pubmed" id="30883663" target="_blank">30883663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24778691">
<a name="24778691"></a>Chang YP. Evidence for adverse effect of perinatal glucocorticoid use on the developing brain. <i>Korean J Pediatr</i>. 2014;57(3):101-109. doi:10.3345/kjp.2014.57.3.101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24778691/pubmed" id="24778691" target="_blank">24778691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16932011">
<a name="16932011"></a>Chanimov M, Koren-Michowitz M, Cohen ML, Pilipodi S, Bahar M. Tumor lysis syndrome induced by dexamethasone. <i>Anesthesiology</i>. 2006;105(3):633-634. doi:10.1097/00000542-200609000-00042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16932011/pubmed" id="16932011" target="_blank">16932011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33216361">
<a name="33216361"></a>Chari A, Rodriguez-Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study. <i>Br J Haematol.</i> 2021;192(5):869-878. doi:10.1111/bjh.16980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33216361/pubmed" id="33216361" target="_blank">33216361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28637662">
<a name="28637662"></a>Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. <i>Blood</i>. 2017;130(8):974-981. doi:10.1182/blood-2017-05-785246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28637662/pubmed" id="28637662" target="_blank">28637662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31433920">
<a name="31433920"></a>Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. <i>N Engl J Med</i>. 2019;381(8):727-738. doi:10.1056/NEJMoa1903455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31433920/pubmed" id="31433920" target="_blank">31433920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7828455">
<a name="7828455"></a>Charles B, Schild P, Steer P, Cartwright D, Donovan T. Pharmacokinetics of dexamethasone following single-dose intravenous administration to extremely low birth weight infants. <i>Dev Pharmacol Ther</i>. 1993;20(3-4):205-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7828455/pubmed" id="7828455" target="_blank">7828455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36156145">
<a name="36156145"></a>Chawla S, Wyckoff MH, Rysavy MA, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Association of antenatal steroid exposure at 21 to 22 weeks of gestation with neonatal survival and survival without morbidities.<i> JAMA Netw Open</i>. 2022;5(9):e2233331. doi:10.1001/jamanetworkopen.2022.33331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/36156145/pubmed" id="36156145" target="_blank">36156145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9407939">
<a name="9407939"></a>Chen JS, Wu JM, Chen YJ, Yeh TF. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 1997;19(6):526-529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9407939/pubmed" id="9407939" target="_blank">9407939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cinvanti.2017.11">
<a name="Cinvanti.2017.11"></a>Cinvanti (aprepitant IV) [prescribing information]. San Diego, CA: Heron Therapeutics, Inc; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24347992">
<a name="24347992"></a>Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. <i>J Pharmacol Pharmacother</i>. 2013;4(suppl 1):S94-S98. doi:10.4103/0976-500X.120975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24347992/pubmed" id="24347992" target="_blank">24347992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18541610">
<a name="18541610"></a>Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. <i>BMJ</i>. 2008;336(7657):1359-1361. doi:10.1136/bmj.39566.806725.BE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18541610/pubmed" id="18541610" target="_blank">18541610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594318">
<a name="12594318"></a>Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. <i>N Engl J Med.</i> 2003;348(8):727-734. doi:10.1056/NEJMra020529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12594318/pubmed" id="12594318" target="_blank">12594318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11779267">
<a name="11779267"></a>Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. <i>JAMA</i>. 2002;287(2):236-240. doi:10.1001/jama.287.2.236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11779267/pubmed" id="11779267" target="_blank">11779267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1403397">
<a name="1403397"></a>Couser RJ, Ferrara TB, Falde B, et al. Effectiveness of dexamethasone in preventing extubation failure in preterm infants at increased risk for airway edema. <i>J Pediatr.</i> 1992;121(4):591-596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/1403397/pubmed" id="1403397" target="_blank">1403397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7630673">
<a name="7630673"></a>Cruz MN, Stewart G, Rosenberg N. Use of dexamethasone in the outpatient management of acute laryngotracheitis. <i>Pediatrics</i>. 1995;96(2 Pt 1):220-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7630673/pubmed" id="7630673" target="_blank">7630673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15634032">
<a name="15634032"></a>Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98. doi:10.2165/00003088-200544010-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15634032/pubmed" id="15634032" target="_blank">15634032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11687075">
<a name="11687075"></a>Davis PG and Henderson-Smart DJ. Intravenous dexamethasone for extubation of newborn infants. <i>Cochrane Database Syst Rev.</i> 2001;(4):CD000308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11687075/pubmed" id="11687075" target="_blank">11687075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12432041">
<a name="12432041"></a>de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis.<i> N Engl J Med</i>. 2002;347(20):1549-1556. doi:10.1056/NEJMoa021334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12432041/pubmed" id="12432041" target="_blank">12432041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11194544">
<a name="11194544"></a>De Laet MH, Dassonville M, Johansson A, et al. Small-bowel perforation in very low birth weight neonates treated with high-dose dexamethasone. <i>Eur J Pediatr Surg.</i> 2000;10(5):323-327. doi:10.1055/s-2008-1072384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11194544/pubmed" id="11194544" target="_blank">11194544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223115">
<a name="23223115"></a>De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, Kendall MC, McCarthy RJ. Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials. <i>Anesth Analg</i>. 2013;116(1):58-74. doi:10.1213/ANE.0b013e31826f0a0a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23223115/pubmed" id="23223115" target="_blank">23223115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Decadron.2019.05">
<a name="Decadron.2019.05"></a>Decadron (dexamethasone) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30928086">
<a name="30928086"></a>Delaleu J, Destere A, Hachon L, Declèves X, Lloret-Linares C. Glucocorticoids dosing in obese subjects: a systematic review. <i>Therapie</i>. 2019;74(4):451-458. doi:10.1016/j.therap.2018.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30928086/pubmed" id="30928086" target="_blank">30928086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20488359">
<a name="20488359"></a>Desandre PL, Quest TE. Management of cancer-related pain. <i>Hematol Oncol Clin North Am</i>. 2010;24(3):643-658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20488359/pubmed" id="20488359" target="_blank">20488359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dexabliss.2020.03">
<a name="Dexabliss.2020.03"></a>Dexabliss (dexamethasone) [prescribing information]. Biloxi, MS: Levins Pharmaceuticals; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DexamethasoneElixier.2008.04">
<a name="DexamethasoneElixier.2008.04"></a>Dexamethasone elixir [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals; April 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7990859">
<a name="7990859"></a>Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting During Chemotherapy for Cancer. The Italian Group for Antiemetic Research. <i>N Engl J Med. </i>1995;332(1):1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7990859/pubmed" id="7990859" target="_blank">7990859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DexamethasoneInj.2017.11">
<a name="DexamethasoneInj.2017.11"></a>Dexamethasone Injection, USP (dexamethasone sodium phosphate) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DexamethasoneInj.2015.12">
<a name="DexamethasoneInj.2015.12"></a>Dexamethasone Injection, USP (dexamethasone sodium phosphate) [prescribing information]. Rockford, IL: Mylan; December 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intensol.2015.02">
<a name="Intensol.2015.02"></a>Dexamethasone tablets, dexamethasone oral solution, Intensol [prescribing information]. East Windsor, New Jersey: Novitium Pharma LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DexamethasoneTabs.2016.03">
<a name="DexamethasoneTabs.2016.03"></a>Dexamethasone tablets and dexamethasone oral solution [prescribing information]. East Windsor, New Jersey: Novitium Pharma LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DexPak.2011.06">
<a name="DexPak.2011.06"></a>DexPak 13 Day TaperPak, 10 Day TaperPak, and 6 Day TaperPak (dexamethasone) [prescribing information]. Richmond, VA: ECR; June 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9464184">
<a name="9464184"></a>Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspective from in vitro and lens culture studies. <i>Exp Eye Res</i>. 1997;65(4):507-516. doi:10.1006/exer.1997.0359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9464184/pubmed" id="9464184" target="_blank">9464184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21666852">
<a name="21666852"></a>Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. <i>Expert Rev Clin Pharmacol</i>. 2011;4(2):233-242. doi:10.1586/ecp.11.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21666852/pubmed" id="21666852" target="_blank">21666852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30403938">
<a name="30403938"></a>Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2018;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30403938/pubmed" id="30403938" target="_blank">30403938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26671818">
<a name="26671818"></a>Dimopoulos MA, Moreau P, Palumbo A, et al; ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncol</i>. 2016a;17(1):27-38. doi:10.1016/S1470-2045(15)00464-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26671818/pubmed" id="26671818" target="_blank">26671818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27705267">
<a name="27705267"></a>Dimopoulos MA, Oriol A, Nahi H, et al; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016b;375(14):1319-1331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27705267/pubmed" id="27705267" target="_blank">27705267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976420">
<a name="26976420"></a>Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016c;34(13):1544-1557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26976420/pubmed" id="26976420" target="_blank">26976420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32682484">
<a name="32682484"></a>Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i>. 2020;396(10245):186-197. doi:10.1016/S0140-6736(20)30734-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32682484/pubmed" id="32682484" target="_blank">32682484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34087126">
<a name="34087126"></a>Dimopoulos MA, Terpos E, Boccadoro M, et al; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncol</i>. 2021;22(6):801-812. doi:10.1016/S1470-2045(21)00128-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/34087126/pubmed" id="34087126" target="_blank">34087126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31223468">
<a name="31223468"></a>Dineen R, Thompson CJ, Sherlock M. Adrenal crisis: prevention and management in adult patients. <i>Ther Adv Endocrinol Metab</i>. 2019;10:2042018819848218. doi:10.1177/2042018819848218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31223468/pubmed" id="31223468" target="_blank">31223468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22241902">
<a name="22241902"></a>Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. <i>Ann Rheum Dis</i>. 2012;71(7):1128-1133. doi:10.1136/annrheumdis-2011-200702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22241902/pubmed" id="22241902" target="_blank">22241902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16396863">
<a name="16396863"></a>Doyle LW, Davis PG, Morley CJ, et al. Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial. <i>Pediatrics. </i>2006;117(1):75-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16396863/pubmed" id="16396863" target="_blank">16396863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24943696">
<a name="24943696"></a>Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. <i>Mayo Clin Proc</i>. 2014;89(6):817-834. doi:10.1016/j.mayocp.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24943696/pubmed" id="24943696" target="_blank">24943696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1097154">
<a name="1097154"></a>Duggan DE, Matalia N, Ditzler, CA, et al. Bioavailability of oral dexamethasone. <i>Clin Pharmacol Ther.</i> 1975;18(2):205-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/1097154/pubmed" id="1097154" target="_blank">1097154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32808988">
<a name="32808988"></a>Dulek DE, Fuhlbrigge RC, Tribble AC, et al. Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute coronavirus disease 2019 in pediatric patients. <i>J Pediatric Infect Dis Soc</i>. 2020;9(6):716-737. doi:10.1093/jpids/piaa098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32808988/pubmed" id="32808988" target="_blank">32808988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082. doi:10.1002/pbc.24508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7700763">
<a name="7700763"></a>Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. <i>Pediatrics.</i> 1995;95(4):584-590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7700763/pubmed" id="7700763" target="_blank">7700763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28017406">
<a name="28017406"></a>Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28017406/pubmed" id="28017406" target="_blank">28017406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32393732">
<a name="32393732"></a>Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). <i>Blood Cancer J</i>. 2020;10(5):53. doi:10.1038/s41408-020-0311-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32393732/pubmed" id="32393732" target="_blank">32393732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dxevo.2019.06">
<a name="Dxevo.2019.06"></a>Dxevo (dexamethasone) [prescribing information]. Ocean Springs, MS: Phlight Pharma.; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9015035">
<a name="9015035"></a>Egerman RS, Pierce WF 4th, Andersen RN, Umstot ES, Carr TL, Sibai BM. A comparison of the bioavailability of oral and intramuscular dexamethasone in women in late pregnancy. <i>Obstet Gynecol</i>. 1997;89(2):276-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9015035/pubmed" id="9015035" target="_blank">9015035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30646235">
<a name="30646235"></a>Ehret DEY, Edwards EM, Greenberg LT, et al. Association of antenatal steroid exposure with survival among infants receiving postnatal life support at 22 to 25 weeks' gestation. <i>JAMA Netw Open</i>. 2018;1(6):e183235. doi:10.1001/jamanetworkopen.2018.3235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30646235/pubmed" id="30646235" target="_blank">30646235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14625670">
<a name="14625670"></a>Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. <i>Intensive Care Med</i>. 2004;30(1):18-32. doi:10.1007/s00134-003-2059-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/14625670/pubmed" id="14625670" target="_blank">14625670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31141632">
<a name="31141632"></a>Facon T, Kumar S, Plesner T, et al; MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. <i>N Engl J Med</i>. 2019;380(22):2104-2115. doi:10.1056/NEJMoa1817249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31141632/pubmed" id="31141632" target="_blank">31141632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33763699">
<a name="33763699"></a>Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i>. 2021;137(26):3616-3628. doi:10.1182/blood.2020008787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33763699/pubmed" id="33763699" target="_blank">33763699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22764363">
<a name="22764363"></a>Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. <i>Am J Psychiatry</i>. 2012;169(5):491-497. doi:10.1176/appi.ajp.2011.11071009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22764363/pubmed" id="22764363" target="_blank">22764363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298665">
<a name="23298665"></a>Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. <i>Diabetes Res Clin Pract</i>. 2013;99(3):277-280. doi:10.1016/j.diabres.2012.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23298665/pubmed" id="23298665" target="_blank">23298665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37604662">
<a name="37604662"></a>Friedman BW, Solorzano C, Kessler BD, et al. Randomized trial comparing low- vs high-dose IV dexamethasone for patients with moderate to severe migraine. <i>Neurology</i>. 2023;101(14):e1448-e1454. doi:10.1212/WNL.0000000000207648<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/37604662/pubmed" id="37604662" target="_blank">37604662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furst.2">
<a name="Furst.2"></a>Furst DE, Saag KG. Glucocorticoid withdrawal. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gahart.1">
<a name="Gahart.1"></a>Gahart BL, Nazareno AR, Ortega MQ. <i>Gahart’s 2021 Intravenous Medications: A Handbook for Nurses and Health Professionals.</i> 37th ed. Elsevier; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gallagher.1">
<a name="Gallagher.1"></a>Gallagher SA, Hackett P. Acute mountain sickness and high altitude cerebral edema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357821">
<a name="21357821"></a>García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. <i>Circulation</i>. 2011;123(10):1108-1115. doi:10.1161/CIRCULATIONAHA.110.973008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21357821/pubmed" id="21357821" target="_blank">21357821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32956604">
<a name="32956604"></a>George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. <i>Ann Intern Med</i>. 2020;173(11):870-878. doi:10.7326/M20-1594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32956604/pubmed" id="32956604" target="_blank">32956604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26337716">
<a name="26337716"></a>George R, Jeba J, Ramkumar G, Chacko AG, Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. <i>Cochrane Database Syst Rev</i>. 2015;(9):CD006716. doi:10.1002/14651858.CD006716.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26337716/pubmed" id="26337716" target="_blank">26337716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22187441">
<a name="22187441"></a>Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. <i>Diabetes Care</i>. 2012;35(1):181-188. doi:10.2337/dc11-1230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22187441/pubmed" id="22187441" target="_blank">22187441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2218744">
<a name="2218744"></a>Giuliana G, Marcianò V, De Cosimo D, D'Angelo M. Effetti sui tessuti parodontali di uno spazzolino a setole "ammortizzate" (Analisi al S.E.M.) [Effect on periodontal tissue of a "cushioned" bristle brush. (S.E.M. analysis)]. <i>Stomatol Mediterr</i>. 1990;10(2):77-82. Italian.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2218744/pubmed" id="2218744" target="_blank">2218744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28398936">
<a name="28398936"></a>Gill N, Sirizzotti N, Johnson D, et al. Endogenous glucocorticoid response to single-dose dexamethasone for croup in children: A pharmacodynamic study. <i>Pediatr Emerg Care</i>. 2020;36(1):50-56. doi:10.1097/PEC.0000000000001142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28398936/pubmed" id="28398936" target="_blank">28398936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2020">
<a name="GINA.2020"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2020. Accessed May 6, 2020. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2021">
<a name="GINA.2021"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst.</i> 2002;94(22):1712-1718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10645522">
<a name="10645522"></a>Gordon P, Rutledge J, Sawin R, Thomas S, Woodrum D. Early postnatal dexamethasone increases the risk of focal small bowel perforation in extremely low birth weight infants. <i>J Perinatol</i>. 1999;19(8 Pt 1):573-577. doi:10.1038/sj.jp.7200269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/10645522/pubmed" id="10645522" target="_blank">10645522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11503101">
<a name="11503101"></a>Gordon PV, Young ML, Marshall DD. Focal small bowel perforation: an adverse effect of early postnatal dexamethasone therapy in extremely low birth weight infants. <i>J Perinatol</i>. 2001;21(3):156-160. doi:10.1038/sj.jp.7200520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11503101/pubmed" id="11503101" target="_blank">11503101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33189178">
<a name="33189178"></a>Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2020;396(10262):1563-1573. doi:10.1016/S0140-6736(20)32292-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33189178/pubmed" id="33189178" target="_blank">33189178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19023528">
<a name="19023528"></a>Gupta P, Bhatia V. Corticosteroid physiology and principles of therapy.<i> Indian J Pediatr</i>. 2008;75(10):1039-1044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19023528/pubmed" id="19023528" target="_blank">19023528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23919213">
<a name="23919213"></a>Guslandi M. Steroid ulcers: Any news? <i>World J Gastrointest Pharmacol Ther</i>. 2013;4(3):39-40. doi:10.4292/wjgpt.v4.i3.39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23919213/pubmed" id="23919213" target="_blank">23919213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hamrahian.1">
<a name="Hamrahian.1"></a>Hamrahian AH, Sanziana R, Milan S. The management of the surgical patient taking glucocorticoids. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462474">
<a name="29462474"></a>Haran M, Schattner A, Kozak N, Mate A, Berrebi A, Shvidel L. Acute steroid myopathy: a highly overlooked entity. <i>QJM</i>. 2018;111(5):307-311. doi:10.1093/qjmed/hcy031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/29462474/pubmed" id="29462474" target="_blank">29462474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25908299">
<a name="25908299"></a>Haywood A, Good P, Khan S, et al. Corticosteroids for the management of cancer-related pain in adults. <i>Cochrane Database Syst Rev.</i> 2015;2015(4):CD010756. doi:10.1002/14651858.CD010756.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25908299/pubmed" id="25908299" target="_blank">25908299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12571466">
<a name="12571466"></a>Hedlund-Treutiger I, Henter JI, Elinder G. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2003;25(2):139-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12571466/pubmed" id="12571466" target="_blank">12571466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics.</i> 2008;121(2):433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hemady.2020.02">
<a name="Hemady.2020.02"></a>Hemady (dexamethasone) [prescribing information]. East Windsor, NJ: Acrotech Biopharma Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35118829">
<a name="35118829"></a>Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. <i>Arthritis Rheumatol</i>. Published online February 3, 2022. doi:10.1002/art.42062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/35118829/pubmed" id="35118829" target="_blank">35118829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11390328">
<a name="11390328"></a>Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. <i>Am J Epidemiol</i>. 2001;153(11):1089-1093. doi:10.1093/aje/153.11.1089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11390328/pubmed" id="11390328" target="_blank">11390328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hesketh.2019">
<a name="Hesketh.2019"></a>Hesketh PJ. Prevention of chemotherapy-induced nausea and vomiting in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 16, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol.</i> 2020a;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11304899">
<a name="11304899"></a>Hochhaus G, Barth J, al-Fayoumi S, et al. Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). <i>J Clin Pharmacol</i>. 2001;41(4):425-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11304899/pubmed" id="11304899" target="_blank">11304899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16404740">
<a name="16404740"></a>Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. <i>Cancer. </i>2006;106(4):931-940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16404740/pubmed" id="16404740" target="_blank">16404740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25471548">
<a name="25471548"></a>Honoré PM, Jacobs R, De Waele E, et al. What do we know about steroids metabolism and 'PK/PD approach' in AKI and CKD especially while on RRT--current status in 2014. <i>Blood Purif</i>. 2014;38(2):154-157. doi:10.1159/000368390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25471548/pubmed" id="25471548" target="_blank">25471548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15850848">
<a name="15850848"></a>Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. <i>Endocrinol Metab Clin North Am</i>. 2005;34(2):371-84, ix. doi:10.1016/j.ecl.2005.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15850848/pubmed" id="15850848" target="_blank">15850848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Horby.2020">
<a name="Horby.2020"></a>Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. Published June 22, 2020. Accessed June 25, 2020. https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23577697">
<a name="23577697"></a>Huang Y, Cai X, Song X, et al. Steroids for preventing recurrence of acute severe migraine headaches: a meta-analysis. <i>Eur J Neurol</i>. 2013;20(8):1184-1190. doi:10.1111/ene.12155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23577697/pubmed" id="23577697" target="_blank">23577697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24330030">
<a name="24330030"></a>Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. <i>J Intern Med</i>. 2014;275(2):104-115. doi:10.1111/joim.12162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24330030/pubmed" id="24330030" target="_blank">24330030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18684744">
<a name="18684744"></a>Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. <i>Ann Rheum Dis</i>. 2009;68(7):1119-1124. doi:10.1136/ard.2008.092163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18684744/pubmed" id="18684744" target="_blank">18684744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol.</i> 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17900234">
<a name="17900234"></a>James ER. The etiology of steroid cataract. <i>J Ocul Pharmacol Ther</i>. 2007;23(5):403-420. doi:10.1089/jop.2006.0067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17900234/pubmed" id="17900234" target="_blank">17900234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-371348">
<a name="371348"></a>James HE, Madauss WC, Tibbs PA, McCloskey JJ, Bean JR. The effect of high dose dexamethasone in children with severe closed head injury. A preliminary report. <i>Acta Neurochir (Wien)</i>. 1979;45(3-4):225-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/371348/pubmed" id="371348" target="_blank">371348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31656440">
<a name="31656440"></a>Janes M, Kuster S, Goldson TM, Forjuoh SN. Steroid-induced psychosis. <i>Proc (Bayl Univ Med Cent)</i>. 2019;32(4):614-615. doi:10.1080/08998280.2019.1629223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31656440/pubmed" id="31656440" target="_blank">31656440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824481">
<a name="20824481"></a>Jordan K, Roila F, Molassiotis A, et al. Antiemetics in Children Receiving Chemotherapy. MASCC/ESMO Guideline Update 2009. <i>Support Care Cancer</i>. 2011;19(suppl 1):S37-S42. doi: 10.1007/s00520-010-0994-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20824481/pubmed" id="20824481" target="_blank">20824481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27105755">
<a name="27105755"></a>Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. <i>Semin Arthritis Rheum</i>. 2016;46(1):133-141. doi: 10.1016/j.semarthrit.2016.03.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27105755/pubmed" id="27105755" target="_blank">27105755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Joshi.1">
<a name="Joshi.1"></a>Joshi GP. Anesthetic management for enhanced recovery after major surgery (ERAS) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23639746">
<a name="23639746"></a>Kale Y, Aydemir O, Ceylan O, Bas AY, Demirel N. Hypertrophic cardiomyopathy after a single dose of dexamethasone in a preterm infant. <i>Pediatr Neonatol</i>. 2015;56(4):268-270. doi:10.1016/j.pedneo.2013.03.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23639746/pubmed" id="23639746" target="_blank">23639746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3980669">
<a name="3980669"></a>Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure.<i> J Clin Endocrinol Metab</i>. 1985;60(5):848-854. doi:10.1210/jcem-60-5-848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/3980669/pubmed" id="3980669" target="_blank">3980669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24515516">
<a name="24515516"></a>Keeney GE, Gray MP, Morrison AK, et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. <i>Pediatrics</i>. 2014;133(3):493-499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24515516/pubmed" id="24515516" target="_blank">24515516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19588321">
<a name="19588321"></a>Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, Children and Adults. <i>Cochrane Database Syst Rev.</i> 2009;(3):CD001000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19588321/pubmed" id="19588321" target="_blank">19588321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3304622">
<a name="3304622"></a>Klöti J, Fanconi S, Zachmann M, Zaugg H. Dexamethasone therapy and cortisol excretion in severe pediatric head injury. <i>Childs Nerv Syst</i>. 1987;3(2):103-105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/3304622/pubmed" id="3304622" target="_blank">3304622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25872578">
<a name="25872578"></a>Komatsu Y, Okita K, Yuki S, et al. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron. <i>Cancer Sci</i>. 2015;106(7):891-895. doi:10.1111/cas.12675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25872578/pubmed" id="25872578" target="_blank">25872578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21334098">
<a name="21334098"></a>Kravitz J, Dominici P, Ufberg J, Fisher J, Giraldo P. Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial [published correction appears in: <i>Ann Emerg Med</i>. 2018;71(1):9]. <i>Ann Emerg Med</i>. 2011;58(2):200-204. doi:10.1016/j.annemergmed.2011.01.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21334098/pubmed" id="21334098" target="_blank">21334098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6621810">
<a name="6621810"></a>Kretschmer H. Prognosis of severe head injuries in childhood and adolescence. <i>Neuropediatrics</i>. 1983;14(3):176-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6621810/pubmed" id="6621810" target="_blank">6621810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9003846">
<a name="9003846"></a>Kühne T, Freedman J, Semple JW, Doyle J, Butchart S, Blanchette VS. Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. <i>J Pediatr</i>. 1997;130(1):17-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9003846/pubmed" id="9003846" target="_blank">9003846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437329">
<a name="28437329"></a>Kumar A, Weber MH, Gokaslan Z, et al. Metastatic spinal cord compression and steroid treatment: a systematic review.<i> Clin Spine Surg</i>. 2017;30(4):156-163. doi:10.1097/BSD.0000000000000528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28437329/pubmed" id="28437329" target="_blank">28437329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932528">
<a name="15932528"></a>Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AYl. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. <i>Clin Experiment Ophthalmol</i>. 2005;33(3):252-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15932528/pubmed" id="15932528" target="_blank">15932528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2399513">
<a name="2399513"></a>Lamiable D, Vistelle R, Sulmont V, Millart H, Caron J, Choisy H. Pharmacocinétique de la dexaméthasone par voie orale chez le sujet obèse [pharmacokinetics of dexamethasone administered orally in obese patients]. <i>Therapie</i>. 1990;45(4):311-314.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2399513/pubmed" id="2399513" target="_blank">2399513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33739404">
<a name="33739404"></a>Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i>. 2021;137(22):3027-3036. doi:10.1182/blood.2020009507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33739404/pubmed" id="33739404" target="_blank">33739404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Laubach.1">
<a name="Laubach.1"></a>Laubach JP. Multiple myeloma: administrations considerations for common therapies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin.</i> 2006;24(2):167-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lee MJ, Guinn D. Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leonard.1">
<a name="Leonard.1"></a>Leonard JM. Central nervous system tuberculosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 9, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332238">
<a name="17332238"></a>Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. <i>Pediatrics.</i> 2007;119(suppl 2):S166-S174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17332238/pubmed" id="17332238" target="_blank">17332238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23947590">
<a name="23947590"></a>Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2013;9(1):30. doi:10.1186/1710-1492-9-30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23947590/pubmed" id="23947590" target="_blank">23947590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22420969">
<a name="22420969"></a>Loblaw DA, Mitera G, Ford M, Laperriere NJ. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. <i>Int J Radiat Oncol Biol Phys</i>. 2012;84(2):312-317. doi:10.1016/j.ijrobp.2012.01.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22420969/pubmed" id="22420969" target="_blank">22420969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26035255">
<a name="26035255"></a>Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. <i>N Engl J Med</i>. 2015;373(7):621-631.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26035255/pubmed" id="26035255" target="_blank">26035255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10506633">
<a name="10506633"></a>Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. <i>J Clin Oncol.</i> 1999;17(10):3299-3306. doi:10.1200/JCO.1999.17.10.3299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/10506633/pubmed" id="10506633" target="_blank">10506633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34425558">
<a name="34425558"></a>Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. <i>Eur J Endocrinol</i>. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/34425558/pubmed" id="34425558" target="_blank">34425558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31248818">
<a name="31248818"></a>Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. <i>Wilderness Environ Med</i>. 2019;30(4S):S3-S18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31248818/pubmed" id="31248818" target="_blank">31248818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20591379">
<a name="20591379"></a>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. <i>Wilderness Environ Med.</i> 2010;21(2):146-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20591379/pubmed" id="20591379" target="_blank">20591379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25498261">
<a name="25498261"></a>Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. <i>Wilderness Environ Med</i>. 2014;25(4)(suppl):S4-S14. doi:10.1016/j.wem.2014.06.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25498261/pubmed" id="25498261" target="_blank">25498261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977425">
<a name="20977425"></a>Lunghi L, Pavan B, Biondi C, et al. Use of Glucocorticoids in Pregnancy. <i>Curr Pharm Des.</i> 2010;16(32):3616-3637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20977425/pubmed" id="20977425" target="_blank">20977425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21985166">
<a name="21985166"></a>Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. <i>Drugs</i>. 2011;71(15):1973‐1987. doi:10.2165/11596240-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21985166/pubmed" id="21985166" target="_blank">21985166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32026434">
<a name="32026434"></a>Malbari F, Staggers KA, Minard CG, Weiner HL, Chintagumpala MM, Levy AS. Provider views on perioperative steroid use for patients with newly diagnosed pediatric brain tumors. <i>J Neurooncol</i>. 2020;147(1):205-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32026434/pubmed" id="32026434" target="_blank">32026434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mathes.1">
<a name="Mathes.1"></a>Mathes BM, Alquire PC. Intralesional corticosteroid injection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 18, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17077333">
<a name="17077333"></a>Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. <i>Blood</i>. 2007;109(4):1401-1407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17077333/pubmed" id="17077333" target="_blank">17077333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29042832">
<a name="29042832"></a>McCallister A, So TY, Stewart J. Evaluation of the efficacy of a onetime injectable dexamethasone administered orally in the pediatric emergency department for asthma exacerbation. <i>J Pediatr Pharmacol Ther</i>. 2017;22(5):326-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/29042832/pubmed" id="29042832" target="_blank">29042832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7794619">
<a name="7794619"></a>McDonnell M, Evans N. Upper and Lower Gastrointestinal Complications With Dexamethasone Despite H2 Antagonists. <i>J Paediatr Child Health.</i> 1995;31(2):152-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7794619/pubmed" id="7794619" target="_blank">7794619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33368142">
<a name="33368142"></a>McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. <i>Cochrane Database Syst Rev</i>. 2020;12(12):CD004454. doi:10.1002/14651858.CD004454.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33368142/pubmed" id="33368142" target="_blank">33368142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32274772">
<a name="32274772"></a>McIntosh JJ. Corticosteroid guidance for pregnancy during COVID-19 pandemic [published online April 9, 2020]. <i>Am J Perinatol</i>. 2020. doi:10.1055/s-0040-1709684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32274772/pubmed" id="32274772" target="_blank">32274772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23982055">
<a name="23982055"></a>Migita K, Sasaki Y, Ishizuka N, et al. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease. <i>Medicine (Baltimore)</i>. 2013;92(5):285-293. doi:10.1097/MD.0b013e3182a72299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23982055/pubmed" id="23982055" target="_blank">23982055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30932732">
<a name="30932732"></a>Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(14):1228-1263. doi:10.1200/JCO.18.02096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30932732/pubmed" id="30932732" target="_blank">30932732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6273180">
<a name="6273180"></a>Miyabo S, Nakamura T, Kuwazima S, Kishida S. A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man. <i>Eur J Clin Pharmacol</i>. 1981;20(4):277-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6273180/pubmed" id="6273180" target="_blank">6273180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460665">
<a name="18460665"></a>Mongelluzzo J, Mohamad Z, Ten Have TR, et al. Corticosteroids and Mortality in Children With Bacterial Meningitis. <i>JAMA.</i> 2008;299(17):2048-2055.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18460665/pubmed" id="18460665" target="_blank">18460665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34097854">
<a name="34097854"></a>Moreau P, Dimopoulos MA, Mikhael J, et al; IKEMA Study Group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i>. 2021;397(10292):2361-2371. doi:10.1016/S0140-6736(21)00592-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/34097854/pubmed" id="34097854" target="_blank">34097854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27119237">
<a name="27119237"></a>Moreau P, Masszi T, Grzasko N, et al; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.<i> N Engl J Med</i>. 2016;374(17):1621-1634. doi:10.1056/NEJMoa1516282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27119237/pubmed" id="27119237" target="_blank">27119237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29866475">
<a name="29866475"></a>Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study [published correction appears in <i>Lancet Oncol</i>. 2018;19(8):e382]. <i>Lancet Oncol</i>. 2018;19(7):953-964. doi:10.1016/S1470-2045(18)30354-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/29866475/pubmed" id="29866475" target="_blank">29866475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549198">
<a name="16549198"></a>Murphy VE, Fittock RJ, Zarzycki PK, et al. Metabolism of Synthetic Steroids by the Human Placenta. <i>Placenta.</i> 2007;28(1):39-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16549198/pubmed" id="16549198" target="_blank">16549198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24833682">
<a name="24833682"></a>Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. <i>BMJ Open</i>. 2014;4(5):e004587. doi:10.1136/bmjopen-2013-004587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24833682/pubmed" id="24833682" target="_blank">24833682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NationalAsthma.2007">
<a name="NationalAsthma.2007"></a>National Asthma Education and Prevention Program. <i>Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma</i>. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22171401">
<a name="22171401"></a>National Collaborating Centre for Cancer (UK). Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression. Cardiff (UK): National Collaborating Centre for Cancer (UK); November 2008. (NICE Clinical Guidelines, No. 75.) <a href="https://www.ncbi.nlm.nih.gov/books/NBK55007/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK55007/</a>. Accessed September 19, 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22171401/pubmed" id="22171401" target="_blank">22171401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2021">
<a name="NIH.2021"></a>National Institutes of Health (NIH). Coronavirus disease (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov" target="_blank">https://www.covid19treatmentguidelines.nih.gov</a>. Updated September 26, 2022. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2">
<a name="NIH.2"></a>National Institutes of Health (NIH). Coronavirus disease (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov" target="_blank">https://www.covid19treatmentguidelines.nih.gov</a>. Updated April 20, 2023. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12075649">
<a name="12075649"></a>Neff SPW, Stapelberg F, Warmington A. Excruciating perineal pain after intravenous dexamethasone. <i>Anaesth Intensive Care</i>. 2002;30(3):370-371.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12075649/pubmed" id="12075649" target="_blank">12075649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21325604">
<a name="21325604"></a>Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21325604/pubmed" id="21325604" target="_blank">21325604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794604">
<a name="31794604"></a>Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Adv.</i> 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31794604/pubmed" id="31794604" target="_blank">31794604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8466274">
<a name="8466274"></a>Ng PC. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. <i>Arch Dis Child. </i>1993;68(3)(spec no):330-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8466274/pubmed" id="8466274" target="_blank">8466274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18077808">
<a name="18077808"></a>Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. <i>N Engl J Med</i>. 2007;357(24):2431-2440. doi:10.1056/NEJMoa070852.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18077808/pubmed" id="18077808" target="_blank">18077808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25905379">
<a name="25905379"></a>Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid therapy and adrenal suppression. In: Feingold KR, Anawalt B, Boyce A, et al, eds. Endotext. MDText.com, Inc; October 19, 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25905379/pubmed" id="25905379" target="_blank">25905379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nieman.1">
<a name="Nieman.1"></a>Nieman LK. Treatment of adrenal insufficiency in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 14, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18334580">
<a name="18334580"></a>Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2008;93(5):1526-1540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18334580/pubmed" id="18334580" target="_blank">18334580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OConnell.2015">
<a name="OConnell.2015"></a>O'Connell MB, Fritsch MA. Musculoskeletal and connective tissue disorders. <i>Fundamentals of Geriatric Pharmacotherapy, 2</i><sup>nd</sup><i> ed</i>. Hutchison LC, Sleeper RB, Eds. ASHP Publications, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19117904">
<a name="19117904"></a>Onland W, Offringa M, De Jaegere AP, et al. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. <i>Pediatrics.</i> 2009;123(1):367-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19117904/pubmed" id="19117904" target="_blank">19117904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27300483">
<a name="27300483"></a>Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. <i>Headache</i>. 2016;56(6):911-940. doi:10.1111/head.12835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27300483/pubmed" id="27300483" target="_blank">27300483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998938">
<a name="3998938"></a>Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone excretion in human milk. <i>J Pediatr.</i> 1985;106(6):1008-1011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/3998938/pubmed" id="3998938" target="_blank">3998938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxford.1">
<a name="Oxford.1"></a>Oxford University News Release. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Accessed on June 18, 2020. https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27557302">
<a name="27557302"></a>Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016;375(8):754-766.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27557302/pubmed" id="27557302" target="_blank">27557302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11091360">
<a name="11091360"></a>Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies. <i>Teratology.</i> 2000;62(6):385-392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11091360/pubmed" id="11091360" target="_blank">11091360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33833623">
<a name="33833623"></a>Parsons S, Tran VL. The trilogy of SARS-CoV-2 in pediatrics (part 1): acute COVID-19 in special populations. <i>J Pediatr Pharmacol Ther</i>. 2021;26(3):220-239. doi:10.5863/1551-6776-26.3.220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33833623/pubmed" id="33833623" target="_blank">33833623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090327">
<a name="29090327"></a>Pastores SM, Annane D, Rochwerg B; Corticosteroid Guideline Task Force of SCCM and ESICM. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Intensive Care Med</i>. 2018;44(4):474-477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/29090327/pubmed" id="29090327" target="_blank">29090327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32970373">
<a name="32970373"></a>Patel P, Olteanu A, Cabral S, Santesso N, Robinson PD, Dupuis LL. Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review. <i>Pediatr Blood Cancer</i>. 2020;67(12):e28716. doi:10.1002/pbc.28716.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32970373/pubmed" id="32970373" target="_blank">32970373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28453189">
<a name="28453189"></a>Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. <i>Pediatr Blood Cancer</i>. 2017;64(10). doi:10.1002/pbc.26542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28453189/pubmed" id="28453189" target="_blank">28453189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24910822">
<a name="24910822"></a>Patt H, Bandgar T, Lila A, Shah N. Management issues with exogenous steroid therapy. <i>Indian J Endocrinol Metab</i>. 2013;17(suppl 3):S612-S617. doi:10.4103/2230-8210.123548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24910822/pubmed" id="24910822" target="_blank">24910822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33923971">
<a name="33923971"></a>Pelewicz K, Miśkiewicz P. Glucocorticoid withdrawal—an overview on when and how to diagnose adrenal insufficiency in clinical practice. <i>Diagnostics (Basel)</i>. 2021;11(4):728. doi:10.3390/diagnostics11040728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/33923971/pubmed" id="33923971" target="_blank">33923971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20471889">
<a name="20471889"></a>Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. <i>Joint Bone Spine</i>. 2011;78(1):41-44. doi:10.1016/j.jbspin.2010.02.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20471889/pubmed" id="20471889" target="_blank">20471889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12944454">
<a name="12944454"></a>Perron G, Dolbec P, Germain J, Béchard P. Perineal pruritus after i.v. dexamethasone administration. <i>Can J Anaesth.</i> 2003;50(7):749-750.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12944454/pubmed" id="12944454" target="_blank">12944454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24596395">
<a name="24596395"></a>Petrocheilou A, Tanou K, Kalampouka E, Malakasioti G, Giannios C, Kaditis AG. Viral croup: diagnosis and a treatment algorithm. <i>Pediatr Pulmonol</i>. 2014;49(5):421-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24596395/pubmed" id="24596395" target="_blank">24596395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824866">
<a name="20824866"></a>Phillips RS, Gopaul S, Gibson F, et al. Antiemetic Medication for Prevention and Treatment of Chemotherapy Induced Nausea and Vomiting in Childhood. <i>Cochrane Database Syst Rev.</i> 2010;(9):CD007786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20824866/pubmed" id="20824866" target="_blank">20824866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924342">
<a name="28924342"></a>Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: An avoidable irreversible blindness. <i>J Curr Glaucoma Pract</i>. 2017;11(2):67-72. doi:10.5005/jp-journals-l0028-1226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28924342/pubmed" id="28924342" target="_blank">28924342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22583383">
<a name="22583383"></a>Pilkey J, Streeter L, Beel A, Hiebert T, Li X. Corticosteroid-induced diabetes in palliative care. <i>J Palliat Med</i>. 2012;15(6):681-689. doi:10.1089/jpm.2011.0513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22583383/pubmed" id="22583383" target="_blank">22583383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27177728">
<a name="27177728"></a>Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes Endocrinol</i>. 2016;4(7):611-629. doi:10.1016/S2213-8587(16)00086-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27177728/pubmed" id="27177728" target="_blank">27177728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11682018">
<a name="11682018"></a>Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: An international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. <i>High Alt Med Biol.</i> 2001;2(3):389-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11682018/pubmed" id="11682018" target="_blank">11682018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32248521">
<a name="32248521"></a>Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. <i>Int J Gynaecol Obstet</i>. 2020;149(3):273-286. doi:10.1002/ijgo.13156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32248521/pubmed" id="32248521" target="_blank">32248521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Portenoy.1">
<a name="Portenoy.1"></a>Portenoy RK, Ahmed E, Keilson YY. Cancer pain management: role of adjuvant analgesics (coanalgesics). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32248521/pubmed" id="32248521" target="_blank">32248521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14745915">
<a name="14745915"></a>Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. <i>Birth Defects Res A Clin Mol Teratol.</i> 2003;67(12):968-970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/14745915/pubmed" id="14745915" target="_blank">14745915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34253540">
<a name="34253540"></a>Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. <i>BMJ</i>. 2021;374:n1380. doi:10.1136/bmj.n1380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/34253540/pubmed" id="34253540" target="_blank">34253540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770441">
<a name="31770441"></a>Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31770441/pubmed" id="31770441" target="_blank">31770441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11445789">
<a name="11445789"></a>Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. <i>J Pediatr</i>. 2001;139(1):20-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11445789/pubmed" id="11445789" target="_blank">11445789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Raajasekar.1">
<a name="Raajasekar.1"></a>Raajasekar AKA, Barola S, Tehrani L, Chandra AB. To push or not to push: the benefit of administering anti-emetics by intravenous push. <i>Blood</i>. 2015;126(23):3314. https://ashpublications.org/blood/article/126/23/3314/90789/To-Push-or-Not-to-Push-The-Benefit-of.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21181954">
<a name="21181954"></a>Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management [published correction appears in <i>Am J Hematol</i>. 2014;89(6):669].<i> Am J Hematol</i>. 2011;86(1):57-65. doi:10.1002/ajh.21913.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21181954/pubmed" id="21181954" target="_blank">21181954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19853510">
<a name="19853510"></a>Rajkumar SV, Jacobus S, Callander NS, et al; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. <i>Lancet Oncol</i>. 2010;11(1):29-37. doi:10.1016/S1470-2045(09)70284-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19853510/pubmed" id="19853510" target="_blank">19853510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19853510">
<a name="19853510"></a>Raju TN, Mercer BM, Burchfield DJ, Joseph GF Jr. Periviable birth: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists.<i> Am J Obstet Gynecol.</i> 2014;210(5):406-417. doi:10.1016/j.ajog.2014.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24725732/pubmed" id="24725732" target="_blank">24725732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21757964">
<a name="21757964"></a>Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. <i>Ophthalmic Res</i>. 2012;47(2):66-80. doi:10.1159/000328630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21757964/pubmed" id="21757964" target="_blank">21757964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678530">
<a name="32678530"></a>RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19 - preliminary report. <i>N Engl J Med</i>. Published online July 17, 2020. doi:10.1056/NEJMoa2021436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32678530/pubmed" id="32678530" target="_blank">32678530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27117874">
<a name="27117874"></a>Rehrer MW, Liu B, Rodriguez M, Lam J, Alter HJ. A randomized controlled noninferiority trial of single dose of oral dexamethasone versus 5 days of oral prednisone in acute adult asthma. <i>Ann Emerg Med</i>. 2016;68(5):608-613. doi:10.1016/j.annemergmed.2016.03.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27117874/pubmed" id="27117874" target="_blank">27117874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6677878">
<a name="6677878"></a>Richter O, Ern B, Reinhardt D, Becker B. Pharmacokinetics of dexamethasone in children. <i>Pediatr Pharmacol (New York)</i>. 1983;3(3-4):329-337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6677878/pubmed" id="6677878" target="_blank">6677878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11099587">
<a name="11099587"></a>Rittichier KK, Ledwith CA. Outpatient Treatment of Moderate Croup With Dexamethasone: Intramuscular Versus Oral Dosing. <i>Pediatrics.</i> 2000;106(6):1344-1348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11099587/pubmed" id="11099587" target="_blank">11099587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.1">
<a name="Roberts.1"></a>Roberts WN. Intraarticular and soft tissue injections: What agent(s) to inject and how frequently? Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32432946">
<a name="32432946"></a>Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. <i>J Clin Oncol.</i> 2020;38(21):2438-2453. doi:10.1200/JCO.20.00611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32432946/pubmed" id="32432946" target="_blank">32432946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3593899">
<a name="3593899"></a>Rohdewald P, Möllmann H, Barth J, Rehder J, Derendorf H. Pharmacokinetics of dexamethasone and its phosphate ester. <i>Biopharm Drug Dispos</i>. 1987;8(3):205-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/3593899/pubmed" id="3593899" target="_blank">3593899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31484647">
<a name="31484647"></a>Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i>. 2019;134(16):1337-1345. doi:10.1182/blood.2019000241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31484647/pubmed" id="31484647" target="_blank">31484647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26034636">
<a name="26034636"></a>Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. <i>Neurooncol Pract</i>. 2015;2(1):6-12. doi:10.1093/nop/npu029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26034636/pubmed" id="26034636" target="_blank">26034636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25533884">
<a name="25533884"></a>Rottenstreich A, Wexler ID, Abu-Libdeh A, Berkun Y. Iatrogenic cushing syndrome due to intranasal dexamethasone. <i>Clin Pediatr (Phila)</i>. 2015;54(12):1215-1257. doi:10.1177/0009922814563927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25533884/pubmed" id="25533884" target="_blank">25533884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23157995">
<a name="23157995"></a>Roxanas MG, Hunt GE. Rapid reversal of corticosteroid-induced mania with sodium valproate: a case series of 20 patients. <i>Psychosomatics</i>. 2012;53(6):575-581. doi:10.1016/j.psym.2012.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23157995/pubmed" id="23157995" target="_blank">23157995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21249651">
<a name="21249651"></a>Russell KF, Liang Y, O'Gorman K, Johnson DW, Klassen TP. Glucocorticoids for croup. <i>Cochrane Database Syst Rev</i>. 2011;(1):CD001955.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21249651/pubmed" id="21249651" target="_blank">21249651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14973975">
<a name="14973975"></a>Russell K, Wiebe N, Saenz A, et al. Glucocorticoids for Croup. <i>Cochrane Database Syst Rev.</i> 2004;(1):CD001955.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/14973975/pubmed" id="14973975" target="_blank">14973975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19957014">
<a name="19957014"></a>Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. <i>J Neurooncol</i>. 2010;96(1):103-114. doi:10.1007/s11060-009-0057-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19957014/pubmed" id="19957014" target="_blank">19957014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32769659">
<a name="32769659"></a>Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). <i>Obstet Gynecol</i>. 2020;136(4):823-826. doi:10.1097/AOG.0000000000004103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32769659/pubmed" id="32769659" target="_blank">32769659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8161268">
<a name="8161268"></a>Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. <i>Ann Surg</i>. 1994;219(4):416-425. doi:10.1097/00000658-199404000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8161268/pubmed" id="8161268" target="_blank">8161268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24007748">
<a name="24007748"></a>San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2013;14(11):1055-1066. doi:10.1016/S1470-2045(13)70380-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24007748/pubmed" id="24007748" target="_blank">24007748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 4, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.1">
<a name="Sexton.1"></a>Sexton DJ. Dexamethasone to prevent neurologic complications of bacterial meningitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.Accessed September 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19602654">
<a name="19602654"></a>Shefrin AE, Goldman RD. Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. <i>Can Fam Physician</i>. 2009;55(7):704-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19602654/pubmed" id="19602654" target="_blank">19602654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18976336">
<a name="18976336"></a>Singh A, Alter HJ, Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature. <i>Acad Emerg Med</i>. 2008;15(12):1223-1233. doi:10.1111/j.1553-2712.2008.00283.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18976336/pubmed" id="18976336" target="_blank">18976336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singh.2011">
<a name="Singh.2011"></a>Singh M, Sharma CS, Rautela RS, Taneja A. Intravenous dexamethasone causes perineal pain and pruritus. <i>J Anesthe Clinic Res</i>. 2011;4:273. doi:10.4172/2155-6148.1000273 http://www.omicsonline.org/intravenous-dexamethasone-causes-perineal-pain-and-pruritus-2155-6148.1000273.pdf .</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SMFM.1">
<a name="SMFM.1"></a>Society for Maternal Fetal Medicine (SMFM) and the Society for Obstetric Anesthesia and Perinatology (SOAP). Revise Labor and Delivery COVID-19 Considerations (April 14, 2020; updated from an earlier version on March 27, 2020). Accessed April 17, 2020. https://www.smfm.org/covidclinical.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22802322">
<a name="22802322"></a>Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. <i>J Clin Oncol</i>. 2012;30(24):2946-2955. doi:10.1200/JCO.2011.39.6820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22802322/pubmed" id="22802322" target="_blank">22802322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16624882">
<a name="16624882"></a>Sparrow A, Geelhoed G. Prednisolone Versus Dexamethasone in Croup: A Randomised Equivalence Trial. <i>Arch Dis Child.</i> 2006;91(7):580-583.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16624882/pubmed" id="16624882" target="_blank">16624882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30272171">
<a name="30272171"></a>Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/30272171/pubmed" id="30272171" target="_blank">30272171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20823466">
<a name="20823466"></a>Speiser PW, Azziz R, Baskin LS, et al; Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline [published correction appear in <i>J Clin Endocrinol Metab.</i> 2010;95(11):5137]. <i>J Clin Endocrinol Metab</i>. 2010;95(9):4133-4160. doi:10.1210/jc.2009-2631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20823466/pubmed" id="20823466" target="_blank">20823466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11150359">
<a name="11150359"></a>Stark AR, Carlo WA, Tyson JE, et al; National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. <i>N Engl J Med</i>. 2001;344(2):95-101. doi:10.1056/NEJM200101113440203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11150359/pubmed" id="11150359" target="_blank">11150359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9751093">
<a name="9751093"></a>Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. <i>Arthritis Rheum</i>. 1998;41(9):1613-1619. doi:10.1002/1529-0131(199809)41:9&lt;1613::AID-ART11&gt;3.0.CO;2-O<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9751093/pubmed" id="9751093" target="_blank">9751093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32876694">
<a name="32876694"></a>Sterne JAC, Murthy S, Diaz, JV; et al. World Health Organization (WHO) Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. <i>JAMA</i>. Published online September 2, 2020. doi:10.1001/jama.2020.17023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32876694/pubmed" id="32876694" target="_blank">32876694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25482145">
<a name="25482145"></a>Stewart AK, Rajkumar SV, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>N Engl J Med</i>. 2015;372(2):142-152. doi:10.1056/NEJMoa1411321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25482145/pubmed" id="25482145" target="_blank">25482145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18256860">
<a name="18256860"></a>Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. <i>Support Care Cancer</i>. 2008;16(9):1041-1048. doi:10.1007/s00520-007-0395-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18256860/pubmed" id="18256860" target="_blank">18256860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26240704">
<a name="26240704"></a>Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. <i>World J Diabetes</i>. 2015;6(8):1073-1081. doi:10.4239/wjd.v6.i8.1073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26240704/pubmed" id="26240704" target="_blank">26240704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TaperDex.2020.02">
<a name="TaperDex.2020.02"></a>TaperDex (dexamethasone) [prescribing information]. Ridgeland, MS: Xspire Pharma; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36337130">
<a name="36337130"></a>Teelucksingh S, Nana M, Nelson-Piercy C. Managing COVID-19 in pregnant women. <i>Breathe (Sheff)</i>. 2022;18(2):220019. doi:10.1183/20734735.0019-2022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/36337130/pubmed" id="36337130" target="_blank">36337130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1993963">
<a name="1993963"></a>Tellez DW, Galvis AG, Storgion SA, et al. Dexamethasone in the Prevention of Postextubation Stridor in Children. <i>J Pediatr.</i> 1991;118(2):289-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/1993963/pubmed" id="1993963" target="_blank">1993963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15496623">
<a name="15496623"></a>Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. <i>N Engl J Med</i>. 2004;351(17):1741-1751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15496623/pubmed" id="15496623" target="_blank">15496623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519450">
<a name="10519450"></a>Tóth GG, Kloosterman C, Uges DR, Jonkman MF. Pharmacokinetics of high-dose oral and intravenous dexamethasone. <i>Ther Drug Monit</i>. 1999;21(5):532-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/10519450/pubmed" id="10519450" target="_blank">10519450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21132302">
<a name="21132302"></a>Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. <i>Rheumatol Int</i>. 2012;32(3):645-653. doi:10.1007/s00296-010-1697-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21132302/pubmed" id="21132302" target="_blank">21132302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096497">
<a name="26096497"></a>Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. <i>Aliment Pharmacol The</i>r. 2015;42(5):599-606. doi:10.1111/apt.13298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26096497/pubmed" id="26096497" target="_blank">26096497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23953794">
<a name="23953794"></a>Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia.<i> Crit Rev Oncol Hematol.</i> 2013;88(3):625-636. doi:10.1016/j.critrevonc.2013.07.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23953794/pubmed" id="23953794" target="_blank">23953794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Recovery.1">
<a name="Recovery.1"></a>University of Oxford. RECOVERY Trial. Accessed July 8, 2020. https://www.recoverytrial.net/.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3541262">
<a name="3541262"></a>Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. <i>Surv Ophthalmol</i>. 1986;31(2):102-110. doi:10.1016/0039-6257(86)90077-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/3541262/pubmed" id="3541262" target="_blank">3541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Updated March 2019. Accessed April 8, 2019. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf." target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12733732">
<a name="12733732"></a>van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. <i>J Bone Miner Res</i>. 2003;18(5):913-918. doi:10.1359/jbmr.2003.18.5.913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12733732/pubmed" id="12733732" target="_blank">12733732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12378366">
<a name="12378366"></a>van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. <i>Osteoporos Int</i>. 2002;13(10):777-787. doi:10.1007/s001980200108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12378366/pubmed" id="12378366" target="_blank">12378366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8164824">
<a name="8164824"></a>Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. <i>Neurology</i>. 1994;44(4):675-680. doi:10.1212/wnl.44.4.675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8164824/pubmed" id="8164824" target="_blank">8164824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32043986">
<a name="32043986"></a>Villar J, Ferrando C, Martínez D, et al; dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. <i>Lancet Respir Med</i>. 2020;8(3):267-276. doi:10.1016/S2213-2600(19)30417-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/32043986/pubmed" id="32043986" target="_blank">32043986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7770303">
<a name="7770303"></a>Wald ER, Kaplan SL, Mason, EO Jr. Dexamethasone therapy for children with bacterial meningitis. <i>Pediatrics. </i>1995;95(1):21-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7770303/pubmed" id="7770303" target="_blank">7770303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28836444">
<a name="28836444"></a>Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. <i>Ann Pharmacother</i>. 2018;52(1):86-90. doi:10.1177/1060028017728297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28836444/pubmed" id="28836444" target="_blank">28836444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11093989">
<a name="11093989"></a>Wang JJ, Ho ST, Lee SC, Liu YC, Ho CM. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study. <i>Anesth Analg</i>. 2000a;91(6):1404-1407. doi:10.1097/00000539-200012000-00019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11093989/pubmed" id="11093989" target="_blank">11093989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10866900">
<a name="10866900"></a>Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. <i>Anesth Analg</i>. 2000b;91(1):136-139. doi:10.1097/00000539-200007000-00025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/10866900/pubmed" id="10866900" target="_blank">10866900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17036562">
<a name="17036562"></a>Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. <i>Mayo Clin Proc</i>. 2006;81(10):1361-1367. doi:10.4065/81.10.1361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17036562/pubmed" id="17036562" target="_blank">17036562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20819899">
<a name="20819899"></a>Watterberg KL; American Academy of Pediatrics. Committee on Fetus and Newborn. Policy Statement--Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. <i>Pediatrics.</i> 2010;126(4):800-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20819899/pubmed" id="20819899" target="_blank">20819899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26480931">
<a name="26480931"></a>Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. <i>Blood</i>. 2016;127(3):296-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26480931/pubmed" id="26480931" target="_blank">26480931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22833532">
<a name="22833532"></a>Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2013;65(3):353-361. doi:10.1002/acr.21812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22833532/pubmed" id="22833532" target="_blank">22833532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23137579">
<a name="23137579"></a>Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. <i>Rheum Dis Clin North Am</i>. 2012;38(4):727-745. doi:10.1016/j.rdc.2012.08.019 23137579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23137579/pubmed" id="23137579" target="_blank">23137579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Corticosteroids for COVID-19: living guidance. Published September 2, 2020. Accessed September 4, 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. Published 2017. Accessed April 9, 2019. https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf;jsessionid=DE537F54942A5274CE53BA18E0FBCC15?sequence=1
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8538233">
<a name="8538233"></a>Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. <i>Mayo Clin Proc</i>. 1996;71(1):5-13. doi:10.4065/71.1.5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8538233/pubmed" id="8538233" target="_blank">8538233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8386285">
<a name="8386285"></a>Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. <i>JAMA</i>. 1993;269(17):2232-2238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8386285/pubmed" id="8386285" target="_blank">8386285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19011472">
<a name="19011472"></a>Yildirim ZK, Büyükavci M, Eren S, Orbak Z, Sahin A, Karakelleoğlu C. Late side effects of high-dose steroid therapy on skeletal system in children with idiopathic thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2008;30(10):749-753. doi:10.1097/MPH.0b013e318180bbc9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19011472/pubmed" id="19011472" target="_blank">19011472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29184808">
<a name="29184808"></a>Younes AK, Younes NK. Recovery of steroid induced adrenal insufficiency. <i>Transl Pediatr</i>. 2017;6(4):269-273. doi:10.21037/tp.2017.10.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/29184808/pubmed" id="29184808" target="_blank">29184808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26611557">
<a name="26611557"></a>Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. <i>Rheum Dis Clin North Am</i>. 2016;42(1):157-176, ix-x. doi:10.1016/j.rdc.2015.08.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26611557/pubmed" id="26611557" target="_blank">26611557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9100 Version 810.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
